US20210353583A1 - Tetrahydrocurcuminoid-metal complexes, manufacturing methods thereof, and uses thereof - Google Patents
Tetrahydrocurcuminoid-metal complexes, manufacturing methods thereof, and uses thereof Download PDFInfo
- Publication number
- US20210353583A1 US20210353583A1 US17/319,496 US202117319496A US2021353583A1 US 20210353583 A1 US20210353583 A1 US 20210353583A1 US 202117319496 A US202117319496 A US 202117319496A US 2021353583 A1 US2021353583 A1 US 2021353583A1
- Authority
- US
- United States
- Prior art keywords
- tetrahydrocurcuminoid
- tetrahydrocurcumin
- curcumin
- animal
- metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 70
- 239000002184 metal Substances 0.000 title claims abstract description 70
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 241001465754 Metazoa Species 0.000 claims abstract description 84
- 239000000203 mixture Substances 0.000 claims abstract description 74
- 230000036541 health Effects 0.000 claims abstract description 34
- 102000004127 Cytokines Human genes 0.000 claims abstract description 32
- 108090000695 Cytokines Proteins 0.000 claims abstract description 32
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 21
- 230000036542 oxidative stress Effects 0.000 claims abstract description 19
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 15
- 230000035882 stress Effects 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 230000036039 immunity Effects 0.000 claims abstract description 12
- 230000007423 decrease Effects 0.000 claims abstract description 8
- 238000002255 vaccination Methods 0.000 claims abstract description 5
- 239000004599 antimicrobial Substances 0.000 claims abstract description 4
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 claims description 226
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 223
- 239000004148 curcumin Substances 0.000 claims description 173
- 229940109262 curcumin Drugs 0.000 claims description 173
- 235000012754 curcumin Nutrition 0.000 claims description 111
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 111
- 239000011701 zinc Substances 0.000 claims description 89
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 78
- 229910052725 zinc Inorganic materials 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 32
- 229930153442 Curcuminoid Natural products 0.000 claims description 25
- 230000003078 antioxidant effect Effects 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 14
- 108090001005 Interleukin-6 Proteins 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 6
- 102000003810 Interleukin-18 Human genes 0.000 claims description 6
- 108090000171 Interleukin-18 Proteins 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 5
- 102000003812 Interleukin-15 Human genes 0.000 claims description 5
- 108090000172 Interleukin-15 Proteins 0.000 claims description 5
- 108090001007 Interleukin-8 Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 229940114124 ferulic acid Drugs 0.000 claims description 5
- 235000001785 ferulic acid Nutrition 0.000 claims description 5
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 5
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 235000003724 spirulina extract Nutrition 0.000 claims description 5
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 5
- KTRRXJQAOOYSDA-UHFFFAOYSA-N 1,7-bis(4-hydroxyphenyl)heptane-3,5-dione Chemical compound C1=CC(O)=CC=C1CCC(=O)CC(=O)CCC1=CC=C(O)C=C1 KTRRXJQAOOYSDA-UHFFFAOYSA-N 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 claims description 3
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims description 3
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 claims description 3
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 claims description 3
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 230000002440 hepatic effect Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 2
- HJFYFYWETUVIHT-UHFFFAOYSA-N tetrahydrodemethoxycurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=CC(O)=CC=2)=C1 HJFYFYWETUVIHT-UHFFFAOYSA-N 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 abstract description 8
- 235000021436 nutraceutical agent Nutrition 0.000 abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- -1 tetrahydrocurcumin-zinc-curcumin Chemical compound 0.000 description 30
- 239000000843 powder Substances 0.000 description 28
- 241000287828 Gallus gallus Species 0.000 description 23
- 235000013330 chicken meat Nutrition 0.000 description 23
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 23
- 239000003446 ligand Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 235000006708 antioxidants Nutrition 0.000 description 19
- 210000000987 immune system Anatomy 0.000 description 19
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 238000010668 complexation reaction Methods 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 241000271566 Aves Species 0.000 description 13
- 239000011592 zinc chloride Substances 0.000 description 13
- 230000009286 beneficial effect Effects 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000011259 mixed solution Substances 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 241000282412 Homo Species 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 229940100601 interleukin-6 Drugs 0.000 description 10
- 150000002739 metals Chemical class 0.000 description 10
- 235000005074 zinc chloride Nutrition 0.000 description 10
- 244000163122 Curcuma domestica Species 0.000 description 9
- 235000003392 Curcuma domestica Nutrition 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000021017 Weight Gain Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 235000003373 curcuma longa Nutrition 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 235000013976 turmeric Nutrition 0.000 description 9
- 230000004584 weight gain Effects 0.000 description 9
- 235000019786 weight gain Nutrition 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000009920 chelation Effects 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 229940076144 interleukin-10 Drugs 0.000 description 6
- 244000144977 poultry Species 0.000 description 6
- 235000013594 poultry meat Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 6
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 5
- 102000000018 Chemokine CCL2 Human genes 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102000008070 Interferon-gamma Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 102000000704 Interleukin-7 Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 229960003130 interferon gamma Drugs 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 230000004572 zinc-binding Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000938605 Crocodylia Species 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 150000002085 enols Chemical class 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000011649 selenium Nutrition 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 150000003751 zinc Chemical class 0.000 description 4
- 0 *C1=C([2*])C=C(CCC(=O)CC(=O)CCC2=CC=C([1*])C([2*])=C2)C=C1 Chemical compound *C1=C([2*])C=C(CCC(=O)CC(=O)CCC2=CC=C([1*])C([2*])=C2)C=C1 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960004308 acetylcysteine Drugs 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000002792 antioxidant assay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 3
- 235000019136 lipoic acid Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010037651 Pyometra Diseases 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000208829 Sambucus Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 201000008680 babesiosis Diseases 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000015111 chews Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229910052741 iridium Inorganic materials 0.000 description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000003244 pro-oxidative effect Effects 0.000 description 2
- 201000002765 pyometritis Diseases 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 2
- WCBPJVKVIMMEQC-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 WCBPJVKVIMMEQC-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101000599932 Gallus gallus Interferon gamma Proteins 0.000 description 1
- 101001033227 Gallus gallus Interleukin-10 Proteins 0.000 description 1
- 101000599062 Gallus gallus Interleukin-6 Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000027109 Headache disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010065433 Ligament rupture Diseases 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000004987 Macrophage activation syndrome Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 108030000436 NADPH:quinone reductases Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100034576 Quinone oxidoreductase Human genes 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 244000058477 Sambucus melanocarpa Species 0.000 description 1
- 235000007052 Sambucus melanocarpa Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000011022 black elderberry Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- PLZFHNWCKKPCMI-UHFFFAOYSA-N cadmium copper Chemical compound [Cu].[Cd] PLZFHNWCKKPCMI-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000008422 cartilage matrix degradation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000000292 ehrlichiosis Diseases 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 150000002843 nonmetals Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 235000020744 piper nigrum extract Nutrition 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000012599 radical scavenging assay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000001060 yellow colorant Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229940032991 zinc picolinate Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
- NHVUUBRKFZWXRN-UHFFFAOYSA-L zinc;pyridine-2-carboxylate Chemical compound C=1C=CC=NC=1C(=O)O[Zn]OC(=O)C1=CC=CC=N1 NHVUUBRKFZWXRN-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/06—Zinc compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention is directed to tetrahydrocurcuminoid-metal complexes and uses of same for maintaining and improving health and/or boosting immunity in animals.
- oxygen free radicals can react with cellular components to damage cells membranes, proteins, and DNA.
- Antioxidants combat the free radicals by donating an electron to the free radical of reactive oxygen species.
- Antioxidants are molecules that prevent free radicals from taking electrons and causing cellular damage.
- Antioxidants are able to give an electron to a free radical without becoming destabilized themselves because they are inherently stable without having a complete electron valence shell.
- antioxidants can stop free radical chain reactions and limit the damage to the body.
- the body has some inherent antioxidants such as glutathione, but obtaining antioxidants from the diet or supplements can help reduce oxidative stress and help the immune system. Once the balance between the accumulation of reactive oxidative species and the removal of oxides is broken, oxidative stress is established. The ultimate consequences of this oxidative stress include tissue damage, inflammation responses, and cell death.
- a strategy to improve general health would be to help reduce oxidative stress and also help the immune system in other more specific ways.
- the challenge is then to find antioxidants that can also boost the immune system.
- the invention is directed in part to tetrahydrocurcuminoid-metal complexes.
- the tetrahydrocurcuminoid-metal complexes are complexes comprising at least one tetrahydrocurcuminoid chelated to a metal.
- the tetrahydrocurcuminoid-metal complexes of the invention encompass tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes and tetrahydrocurcuminoid-metal-curcuminoid complexes.
- the metal can be zinc or other metals.
- the molecular complex can be combined with additional interferon boosting nutraceuticals, such as Spirulina extracts, lipoic acid, ferulic acid, N-acetyl cysteine, or other nutraceuticals.
- the tetrahydrocurcuminoid-metal complexes can be orally or topically delivered to animals for the purpose of stimulating the immune system in times of stress from diseases or other causes of stress to help maintain general health.
- animals include mammals, fish, birds, and reptiles.
- the invention helps animals achieve better overall health, especially in times of oxidative stress, such as from diseases or to maintain optimum immunity health on a daily basis.
- the tetrahydrocurcuminoid-metal complex compositions can be combined with other immune modulating agents to further enhance bioavailability and antioxidant capability to achieve optimal health.
- the invention in some aspects encompasses a chelation of zinc or other metals to a tetrahydrocurcuminoid and a curcuminoid simultaneously.
- the molecular complex of the invention further advances the art of stimulating the immune system by providing both tetrahydrocurcuminoids with curcuminoids orally or topically instead of relying on the body to metabolize curcuminoids into tetrahydrocurcuminoids, as tetrahydrocurcuminoids are not found in turmeric extracts.
- curcuminoids and tetrahydrocurcuminoids have distinct benefits over one and another, the invention further advances the art by taking the advantages of both.
- the invention further advances the art by creating molecular tetrahydrocurcuminoid-metal-curcuminoid complexes that synergistically increase the antioxidant and immune stimulating capability of both tetrahydrocurcuminoids, such as tetrahydrocurcumin, and curcuminoids, such as curcumin.
- tetrahydrocurcuminoids such as tetrahydrocurcumin
- curcuminoids such as curcumin.
- FIG. 1 Exemplary curcumin-metal complex structures.
- FIG. 2 Structure of an exemplary curcumin-metal-curcumin complex.
- FIG. 3 Structure of an exemplary tetrahydrocurcumin-metal-curcumin complex of the invention.
- FIG. 4 3D model structures of an exemplary tetrahydrocurcumin-metal-curcumin complex of the invention.
- FIGS. 5A-5C UV profiles of tetrahydrocurcumin ( FIG. 5A ), a tetrahydrocurcumin-Zn complex of the invention created at pH 2 ( FIG. 5B ), and a tetrahydrocurcumin-Zn complex of the invention created at pH 7.5 ( FIG. 5C ).
- FIG. 6 FTIR profiles of tetrahydrocurcumin ( FIG. 6A ), a tetrahydrocurcumin-Zn complex of the invention created at pH 2 ( FIG. 6B ), and a tetrahydrocurcumin-Zn complex of the invention created at pH 7.5 ( FIG. 6C ).
- FIGS. 7A-7F Sephadex G-10 purification of different ratios of curcumin:tetrahydrocurcumin (THC) when complexed with zinc at pH 4.0 ( FIGS. 7A, 7C, and 7E ) or pH 7.0 ( FIGS. 7B, 7D, and 7F ).
- THC curcumin:tetrahydrocurcumin
- FIGS. 8A and 8B UV profiles of Sephadex G10-purified red-colored ( FIG. 8A ) and yellow/white-colored ( FIG. 8B ) zinc complexes of curcumin and tetrahydrocurcumin generated with a 25:75 curcumin:tetrahydrocurcumin ratio.
- FIGS. 9A and 9B FTIR profiles of Sephadex G1-purified red-colored ( FIG. 9A ) and yellow/white-colored ( FIG. 9B ) zinc complexes of curcumin and tetrahydrocurcumin generated with a 25:75 curcumin:tetrahydrocurcumin ratio.
- FIGS. 10A and 10B % net uptake of tetrahydrocurcumin (THC) and zinc complexes thereof ( FIG. 10A ) and curcumin and zinc complexes thereof ( FIG. 10B ) across IPEC-J2 cell membranes as determined by HPLC.
- THC tetrahydrocurcumin
- FIG. 11 Time course of bioavailability in blood of curcumin, tetrahydrocurcumin (THC), and a THC-zinc-curcumin complex.
- FIGS. 12A-12C HPLC at 280 nm of serum of chickens fed curcumin ( FIG. 12A ), tetrahydrocurcumin-zinc-curcumin complex (THC-Zn-Curcumin) ( FIG. 12B ), and tetrahydrocurcumin (THC) ( FIG. 12C ) at 2-hour, 4-hour, and 24-hour timepoints after feeding.
- FIGS. 13A-13C HPLC at 425 nm of serum of chickens fed curcumin ( FIG. 13A ), tetrahydrocurcumin-zinc-curcumin complex (THC-Zn-Curcumin) ( FIG. 13B ), and tetrahydrocurcumin (THC) ( FIG. 13C ) at 2-hour, 4-hour, and 24-hour timepoints after feeding.
- FIGS. 14A and 14B Average weights ( FIG. 14A ) and average feed conversion rates ( FIG. 14B ) of chickens fed 0% w/w, 0.5% w/w, or 1% w/w of tetrahydrocurcumin-zinc-curcumin complex for six weeks.
- FIGS. 15A-15D Levels of IL-1-beta ( FIG. 15A ), IL-6 ( FIG. 15B ), IL-10 ( FIG. 15C ), and interferon gamma ( FIG. 15D ) in chickens fed 0% w/w, 0.5% w/w, or 1% w/w of tetrahydrocurcumin-zinc-curcumin complex for six weeks.
- FIG. 16 Antioxidant activity of curcumin (0.125 mg/ml, 0.25, mg/ml, 0.5 mg/ml), tetrahydrocurcumin (THC) (0.125 mg/ml, 0.25, mg/ml, 0.5 mg/ml), and tetrahydrocurcumin (THC)-Zn-curcumin (0.125 mg/ml, 0.25, mg/ml, 0.5 mg/ml) as determined by DPPH (2,2-diphenyl-1-picryl-hydrazyl-hydrate) antioxidant assay.
- THC tetrahydrocurcumin
- FIGS. 17A-17I Release of indicated cytokines from MDCK cells not stimulated with lipopolysaccharide (LPS) ( ⁇ ); stimulated with LPS (8 ⁇ g/ml) in the absence of tetrahydrocurcumin-Zn-curcumin (+); stimulated with LPS (8 ⁇ g/ml) in the presence of 0.125 mg/ml tetrahydrocurcumin-Zn-curcumin (0.125T+L), 0.25 mg/ml tetrahydrocurcumin-Zn-curcumin (0.25T+L), 0.5 mg/ml tetrahydrocurcumin-Zn-curcumin (0.5T+L), or 1 mg/ml tetrahydrocurcumin-Zn-curcumin (1T+L); or treated with 0.125 mg/ml tetrahydrocurcumin-Zn-curcumin (0.125T), 0.25 mg/ml tetrahydrocurcumin-Zn-curcumin
- the invention in some aspects is directed to complexes comprising at least one tetrahydrocurcuminoid chelated to a metal (tetrahydrocurcuminoid-metal complexes).
- Chelation is a type of chemical bonding of ions and molecules to metal ions. It involves the formation or presence of two or more separate coordinate bonds between a polydentate (multiple bonded) ligand and a single central atom. The ionic form of the central atom can be critical to the success of chelation to the ligand, as divalent ions and trivalent ions do not always bind in the same manner.
- Various zinc forms can be utilized in the invention including zinc chloride, zinc acetate, zinc gluconate, zinc sulfate, zinc picolinate in anhydrous or hydrated formats.
- Other ionic metals can be used including iron, copper, cadmium, and iridium in the chelation bonding mechanism.
- Zinc is considered to be relatively nontoxic, particularly if taken orally.
- manifestations of overt toxicity symptoms (nausea, vomiting, epigastric pain, lethargy, and fatigue) will occur with extremely high zinc intakes.
- Even lower levels of zinc supplementation, closer in amount to the recommended daily allowance (RDA) have been suggested to interfere with the utilization of copper and iron and to adversely affect HDL cholesterol concentrations.
- Individuals using zinc supplements should be aware of the possible complications attendant to their use. (Fosmire). As such, it is desirable to get the benefits of zinc in as low a dose as possible.
- curcumin from the turmeric plant (Curcumin longa ).
- Turmeric has been widely used as a spice in Indian food for thousands of years and contains a variety of constituents including curcuminoids such as curcumin, demethoxycurcumin and bisdemethoxycurcumin.
- Curcumin is the most widely known of these curcuminoids and is a naturally occurring polyphenolic phytoconstituent, isolated from turmeric rhizomes with uses as natural yellow colorant along with its use a spice in food. Curcumin also has many health benefits ranging from its anti-inflammatory actions in joints as an oxidative stress reducer to its anti-viral actions. Curcumin and curcuminoids interfere with the activity of a protein in the viruses used to invade the host cells. By doing so, the curcumin and curcuminoids prevent replications of the virus. Curcumin can reduce viral replication by over 90 percent in laboratory cells infected with influenza varieties. Curcumin decreases viral replication in infected cells, but also seems to protect other cells from becoming infected. Curcumin can also boost beta interferon levels reduce oxidative stress during influenza (Dai).
- Curcumin is insoluble in water under acidic or neutral conditions. Curcumin is unstable by undergoing rapid hydrolytic degradation in neutral or alkaline conditions. Since it is insoluble in aqueous medium and has poor stability towards oxidation, light, alkalinity, enzymes and heat, curcumin cannot really be widely used in pharmaceutical preparations unless stability issues can be overcome.
- Turmeric and extracts with curcuminoids are considered safe when taken orally and when used topically by most people. Turmeric products that provide up to 8 grams of curcumin daily appear to be safe when used for up to 2 months (e.g., 0.05 g curcumin/lb. body weight). Turmeric typically does not cause serious side effects. Some people can experience mild side effects such as stomach upset, nausea, dizziness, or diarrhea. These side effects are more common at higher doses. However, under certain health conditions, curcumin can cause problems with people with gallbladder problems, bleeding problems where turmeric might slow blood clotting, in diabetes where curcumin might decrease blood sugar in diabetic people, after surgery where turmeric might slow blood clotting and other possible situations. As such, being able to use less curcumin to achieve its beneficial health effects rather than higher amounts of curcumin is desirable.
- Curcumin is a ligand that forms stable complexes with certain metal ions and nonmetals. In general, stable structures with 1:1, 2:1 and 3:1 (ligand:metal) stoichiometry can occur. Complexation of curcumin with aluminum, copper, or iron has been used for the treatment of Alzheimer's disease and with zinc for increases in vitro antioxidant activity.
- curcumin When curcumin is ingested, it is metabolized by cells.
- One of the major metabolites of curcumin is tetrahydrocurcumin (THC), which lacks the ⁇ , ⁇ -unsaturated carbonyl moiety and is white in color whereas curcumin is a yellow color.
- THC tetrahydrocurcumin
- Tetrahydrocurcumin is not found in turmeric plants and has to be metabolized from curcumin by the body.
- Curcumin and tetrahydrocurcumin exhibit different biological properties. Tetrahydrocurcumin exhibits higher antioxidant activity, whereas curcumin exhibits both pro-oxidant and antioxidant properties. Curcumin appears to bind to and modulate the activities of a wide variety of targets.
- Tetrahydrocurcumin appears to be a superior antioxidant that lacks both anti-inflammatory and pro-oxidant activities. (Aggarwal). Tetrahydrocurcumin is superior to curcumin for induction of glutathione peroxidase, glutathione-S-transferase, and NADPH: quinone reductase, and the quenching of free radicals. It is possible that curcumin and tetrahydrocurcumin are taken up and metabolized differently in cells, which thus determines their biological activity. However, curcumin offers antiviral capability against the flu. Therefore, if possible, one should use both curcumin and tetrahydrocurcumin to boost the immune system to get advantages of both.
- tetrahydrocurcumin also is not very water soluble. This makes both curcumin and tetrahydrocurcumin poorly bioavailable and problematic for practical uses in readily boosting the immune system in supplements. As such, there is a need to develop methods to increase tetrahydrocurcumin bioavailability and stability.
- This novel complex molecule solves the problems of stability and bioavailability of curcumin and tetrahydrocurcumin and further allows for a single molecule to have the health effects of both curcumin and tetrahydrocurcumin to synergistically occur efficiently.
- nutraceuticals can help boost type 1 interferon levels in the cell.
- Elderberry Sambucus
- nutraceuticals can complement the activities of the tetrahydrocurcuminoid-metal-curcuminoid complexes of the invention in boosting the immune system or maintaining optimum immunity on a daily basis.
- tetrahydrocurcuminoid refers to a compound having the structure:
- each R 1 and R 2 are independently selected from the group consisting of H, OH, and OCH 3 , and salts, esters, tautomers (e.g., enols), and chelates thereof.
- each R 1 is independently selected from the group consisting of H and OH.
- each R 1 is OH.
- each R 2 is selected from the group consisting of H and OCH 3 .
- each R 2 is OCH 3 .
- each R 2 is H.
- one R 2 is OCH 3
- one R 2 is H.
- Exemplary tetrahydrocurcuminoids include tetrahydrocurcumin, wherein each R 1 is OH, and each R 2 is OCH 3 ; tetrahydrodemethoxycurcumin, wherein each R 1 is OH, one R 2 is OCH 3 , and one R 2 is H; and tetrahydrobisdemethoxycurcumin, wherein each R 1 is OH, and each R 2 is H.
- curcuminoid refers to a compound having the structure:
- each R 1 and R 2 are independently selected from the group consisting of H, OH, and OCH 3 , and salts, esters, tautomers (e.g., enols), and chelates thereof.
- each R 1 is independently selected from the group consisting of H and OH.
- each R 1 is OH.
- each R 2 is selected from the group consisting of H and OCH 3 .
- each R 2 is OCH 3 .
- each R 2 is H.
- one R 2 is OCH 3
- one R 2 is H.
- curcuminoids include curcumin, wherein each R 1 is OH, and each R 2 is OCH 3 ; demethoxycurcumin, wherein each R 1 is OH, one R 2 is OCH 3 , and one R 2 is H; and bisdemethoxycurcumin, wherein each R 1 is OH, and each R 2 is H.
- tetrahydrocurcuminoid-metal complex refers to a complex comprising at least one tetrahydrocurcuminoid chelated to a metal. Some tetrahydrocurcuminoid-metal complexes of the invention include more than one tetrahydrocurcuminoid chelated to the metal. Some tetrahydrocurcuminoid-metal complexes of the invention include at least one one tetrahydrocurcuminoid chelated to the metal in addition to another compound chelated to the metal.
- Exemplary tetrahydrocurcuminoid-metal complexes include tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes and tetrahydrocurcuminoid-metal-curcuminoid complexes.
- tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complex refers to a complex comprising at least two tetrahydrocurcuminoids chelated to a common metal.
- tetrahydrocurcuminoid-metal-curcuminoid complex refers to a complex comprising at least one tetrahydrocurcuminoid and at least one curcuminoid chelated to a common metal.
- curcuminoid-metal-curcuminoid complex refers to a complex comprising two curcuminoids chelated to a common metal.
- the metal in the curcuminoid-metal-curcuminoid complexes, tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes, and tetrahydrocurcuminoid-metal-curcuminoid complexes can be a divalent metal or a trivalent metal.
- Exemplary suitable divalent metals include zinc, copper cadmium, and cobalt.
- Exemplary suitable trivalent metals include iron, ruthenium, iridium, and aluminum.
- An exemplary structure of a tetrahydrocurcuminoid-metal-curcuminoid complex of the invention is:
- each R 1 and R 2 are independently selected from the group consisting of H, OH, and OCH 3 , and salts and esters thereof.
- each R 1 is independently selected from the group consisting of H and OH.
- each R 1 is OH.
- each R 2 is selected from the group consisting of H and OCH 3 .
- each R 2 is OCH 3 .
- each R 2 is H.
- one R 2 is OCH 3
- three R 2 are H.
- two R 2 are OCH 3
- two R 2 are H.
- three R 2 are OCH 3 , and one R 2 is H.
- a first ligand e.g., tetrahydrocurcuminoid
- second ligand e.g., curcuminoid
- a suitable solvent e.g., water
- 0.5 parts by number (e.g., 0.5 mole) of one or more tetrahydrocurcuminoids and 0.5 parts by number (e.g., 0.5 mole) of one or more curcuminoids can be solubilized together in an organic solvent such as methanol, ethanol, glycerol, propylene glycol, or other suitable solvent.
- tetrahydrocurcuminoid/curcuminoid ligand with each ligand in a 1:1 ratio by number.
- Other relative ratios of tetrahydrocurcuminoid:curcuminoid can be used depending on the requirements of the final product.
- Exemplary tetrahydrocurcuminoid:curcuminoid ratios include 100:1, 75:1, 50:1, 25:1, 10:1, 7:1, 3:1, 1:1, 1:3, 1:7, 1:10, 1:25, 1:50, 1:75, and 1:100, any ranges between these exemplary ratios, or any and ratios or ranges above or below these exemplary ratios.
- metal e.g., zinc
- number e.g., 1 mole
- a suitable solvent such as water or organic solvent, depending on the format of the metal.
- the solubilized metal can then be combined with the solubilized ligand, preferably in a 1:1 number ratio of metal to generate a mixed solution.
- Other ratios of metal can be used.
- Exemplary metal:ligand ratios include 100:1, 75:1, 50:1, 25:1, 10:1, 7:1, 3:1, 1:1, 1:3, 1:7, 1:10, 1:25, 1:50, 1:75, and 1:100, any ranges between these exemplary ratios, or any and ratios or ranges above or below these exemplary ratios.
- the mixed solution can optionally have its pH adjusted to a pH from about 6.5 to about 8.5.
- the pH adjustment can be performed with a reagent such as triethylamine, sodium hydroxide, potassium hydroxide, and/or sodium bicarbonate.
- the combined metal and ligand in the mixed solution can be stirred at room temperature or higher for 2 hours or longer as required for complexation to occur.
- the solvent can then be removed from the complexed composition by filtration or other means, washed in water as required to remove unreacted metal, and further dried to create a powder.
- Analysis of the complex can be carried to quantify the metal content of the complex.
- Ultraviolet (UV) and Fourier-transform infrared spectroscopy (FTIR) analysis methods can be used to determine that complexation has occurred by comparing to control ligand.
- the powder can be mixed with other components, such anti-inflammatory agents, immune boosting agents, antioxidants, phytobotanicals, and/or carriers.
- the methods of making the tetrahydrocurcuminoid-metal complexes of the invention can comprise: solubilizing one or more first compounds in a first solvent to form a first solution, wherein the one or more first compounds comprises a tetrahydrocurcuminoid; solubilizing a metal in a second solvent to form a second solution; mixing the first solution with the second solution to thereby form a mixed solution comprising the one or more first compounds, the metal, and a mixed solvent comprising the first and second solvents; and incubating the mixed solution for a time and a temperature suitable for generating the tetrahydrocurcuminoid-metal complex.
- the one or more first compounds further comprises a curcuminoid.
- the methods can further comprise: solubilizing one or more third compounds in a third solvent to form a third solution, wherein the one or more third compounds comprises a curcuminoid; and mixing the third solution with the first solution and the second solution to thereby form the mixed solution, wherein the mixed solution comprises the one or more first compounds, the one or more second compounds, the metal, and the mixed solvent comprising the first, second, and third solvents.
- the methods can further comprise, after the incubating, removing the mixed solvent from the tetrahydrocurcuminoid-metal complex.
- the methods can further comprise, after the removing, drying the tetrahydrocurcuminoid-metal complex into a powder.
- the methods can further comprise, prior to or during the incubating, adjusting the pH of the mixed solution to a pH of from 6.5 to 8.5.
- the adjusting comprises adding at least one of triethylamine, sodium hydroxide, potassium hydroxide, and sodium bicarbonate to the mixed solution.
- the incubating is conducted at a pH from 6.5 to 8.5.
- the methods of making the tetrahydrocurcuminoid-metal complexes of the invention can comprise incubating one or more first compounds and a metal in a solvent for a time and a temperature suitable for generating the tetrahydrocurcuminoid-metal complex.
- the one or more first compounds comprises a tetrahydrocurcuminoid.
- the one or more first compounds further comprises a curcuminoid.
- the methods can further comprise, after the incubating, removing the mixed solvent from the tetrahydrocurcuminoid-metal complex.
- the methods can further comprise, after the removing, drying the tetrahydrocurcuminoid-metal complex into a powder.
- the methods can further comprise, prior to or during the incubating, adjusting the pH of the mixed solution to a pH of from 6.5 to 8.5.
- the adjusting comprises adding at least one of triethylamine, sodium hydroxide, potassium hydroxide, and sodium bicarbonate to the mixed solution.
- the incubating is conducted at a pH from 6.5 to 8.5.
- the one or more first compounds and the metal are mixed in dry form prior to mixing with the solvent.
- the one or more first compounds and the metal are each added separately in dry form to the solvent.
- compositions Compositions, Components Thereof, and Uses Thereof
- the tetrahydrocurcuminoid-metal complexes of the invention can be included in a composition suitable for administration to an animal.
- the composition can be suitable for oral administration or topical administration.
- the compositions can be in a solid form, a liquid form, or a semi-solid form (e.g., gel, paste, cream). Exemplary solid forms include powder, tablets, etc.
- the tetrahydrocurcuminoid-metal complexes can be included in the composition in an amount from 0.0000000001% w/w to 99.999999999% w/w.
- Exemplary amounts include 0.1% w/w, 5% w/w, 10% w/w, 15% w/w, 20% w/w, 25% w/w, 30% w/w, 35% w/w, 40% w/w, 45% w/w, 50% w/w, 55% w/w, 60% w/w, 65% w/w, 70% w/w, 75% w/w, 80% w/w, 85% w/w, 90% w/w, or 95% w/w; any range between these amounts, or any amount or range above or below these amounts.
- the composition includes a combination of tetrahydrocurcuminoid-metal-curcuminoid complexes and tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes; tetrahydrocurcuminoid-metal-curcuminoid complexes and curcuminoid-metal-curcuminoid complexes; tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes and curcuminoid-metal-curcuminoid complexes; or tetrahydrocurcuminoid-metal-curcuminoid complexes, tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes, and curcuminoid-metal-curcuminoid complexes.
- the combination can be included in the composition in an amount from 0.0000000001% w/w to 99.999999999% w/w.
- Exemplary amounts include 0.1% w/w, 5% w/w, 10% w/w, 15% w/w, 20% w/w, 25% w/w, 30% w/w, 35% w/w, 40% w/w, 45% w/w, 50% w/w, 55% w/w, 60% w/w, 65% w/w, 70% w/w, 75% w/w, 80% w/w, 85% w/w, 90% w/w, or 95% w/w; any range between these amounts, or any amount or range above or below these amounts.
- the composition can include any of a number of additional components, such as inert carriers and/or active ingredients. Each additional component can be included in the composition in an amount from 0.0000000001% w/w to 99.999999999% w/w. Exemplary amounts include 0.1% w/w, 5% w/w, 10% w/w, 15% w/w, 20% w/w, 25% w/w, 30% w/w, 35% w/w, 40% w/w, 45% w/w, 50% w/w, 55% w/w, 60% w/w, 65% w/w, 70% w/w, 75% w/w, 80% w/w, 85% w/w, 90% w/w, or 95% w/w; any range between these amounts, or any amount or range above or below these amounts.
- Active ingredients are ingredients other than the tetrahydrocurcuminoid-metal complexes of the invention having therapeutic or other value when administered to an animal, such as drugs, nutrients, cosmeceuticals, diagnostic agents, nutritional agents, and the like.
- active ingredients include anti-inflammatory agents, antioxidants, antimicrobial agents, and immune boosters.
- antioxidants include phytobotanicals, anthocyanins, polyphenols, ferulic acid, N-acetyl cysteine, Spirulina extracts, selenium, lipoic acid, yeast beta glucans, and glucosamine.
- Exemplary antimicrobial agents include phytobotanicals.
- Exemplary immune boosting agents include zinc and selenium.
- Exemplary inert carriers include water or other inert carriers known in the art.
- each of the components in the final product may be varied depending upon the nature of the additional components, the weight and condition of the animal to be treated, and the unit dosage desired. Those of ordinary skill in the art will be able to adjust dosage amounts as required.
- compositions of the invention include soft chews, powders, capsules, tablets, boluses, pastes, liquids, foods, animal feeds, candies, drinks, pastes, liquids, and creams.
- Exemplary composition forms suitable for oral administration include tablets, boluses, pastes, capsules, liquids, such as human foods, animal feeds, candy, soft chews, or drinks.
- Exemplary composition forms suitable for topical administration include pastes, liquids, gels, or creams.
- the components of the invention can be placed into capsules, boluses, and tablets for oral administration or in pastes, liquids, gels, or creams for topical administration in times of oxidative stress from diseases or to maintain optimum immunity health on a daily basis.
- the components of the invention may also be placed into human foods and animal feeds including cereals, soups, liquid drinks, candy, pharmaceuticals aids including band aids, skin care beauty creams, and pastes.
- Some versions of the invention include the tetrahydrocurcuminoid-metal complex in combination with any one or more, in any combination, of black elderberry (a phytonutrient supporting immune function and promoting a healthy respiratory system), selenium (a micronutrient that helps fight cellular damage), vitamin D3 (builds immunity in times of stress), vitamin C (ascorbic acid, an antioxidant for maintaining production of white blood cells), phycocyanin (a Spirulina extract that provides support by helping to maintain normal interferon levels during oxidative stress), ferulic acid (an organic compound with antioxidant properties that support the body during stress), and piperine (black pepper extract that helps the body by increasing bioavailability of nutraceuticals like curcumin).
- black elderberry a phytonutrient supporting immune function and promoting a healthy respiratory system
- selenium a micronutrient that helps fight cellular damage
- vitamin D3 builds immunity in times of stress
- vitamin C ascorbic acid, an antioxidant for maintaining production of white blood cells
- phycocyanin a
- compositions can be used in methods of reducing stress, reducing oxidative stress, maintaining health, improving health, improving immunity, improving vaccination efficacy, increasing feed conversion rate, or decreasing pro-inflammatory cytokine levels in an animal in an animal (such as a mammal, human, poultry, etc.).
- the methods can comprise administering a composition of the invention to the animal in a therapeutically effective amount.
- the therapeutically effective amount can include an amount effective to reduce stress, reduce oxidative stress, maintain health, improve health, improve immunity, improve vaccination efficacy, increase feed conversion rate, or decrease pro-inflammatory cytokine levels in an animal.
- the animal in some versions can include an animal suffering from any condition or disease described herein.
- exemplary diseases include cancer, arthritis, inflammatory conditions, cardiovascular conditions, neurological conditions, pulmonary conditions, diabetes, hepatic conditions, gastrointestinal conditions, and an infectious disease, and other conditions that place stresses on the body.
- Exemplary cardiovascular conditions comprise coronary artery disease, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, and cardiomyopathy, among others.
- Exemplary neurological conditions comprise diseases of the central and peripheral nervous system, including the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscles.
- pulmonary conditions include epilepsy, Alzheimer disease and other dementias, cerebrovascular diseases including stroke, migraine and other headache disorders, multiple sclerosis, Parkinson's disease, neuroinfections, brain tumors, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition.
- pulmonary conditions include asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, lung cancer, cystic fibrosis/bronchiectasis, pneumonia, pleural effusion, and COVID-19.
- exemplary forms of diabetes include type 1 diabetes and type 2 diabetes.
- Exemplary hepatic conditions comprise hepatitis A infection, hepatitis B infection, and hepatitis C infection, fatty liver disease, cirrhosis, liver cancer, and inherited diseases such as hemochromatosis and Wilson disease.
- Exemplary gastrointestinal conditions comprise celiac disease, irritable bowel syndrome, and irritable bowel disease (Crohn's disease, ulcerative colitis).
- Exemplary infectious diseases include viral diseases, prion diseases, and bacterial diseases.
- the animal can include an animal to be or having been vaccinated within a period of 8 weeks, 7 weeks, 6 weeks, 5 weeks, 4 weeks, 3 weeks, 2 weeks, 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day.
- the therapeutically effective amount can be an amount effective to ameliorate the condition or disease or a symptom of the condition or disease.
- the animal can comprise any animal.
- the animal can comprise a human or a non-human animal.
- the animal can comprise a mammal. Exemplary mammals include humans, bovines, swine, sheep, goats, dogs, cats, primates, apes, monkeys, and rodents.
- the animal can comprise a bird, such as poultry.
- the animal can comprise other types of animal, such as fish or reptiles.
- the animal comprises a production animal. Production animals are animals that are farmed for food or products derived therefrom.
- Exemplary production animals include bovines (including cattle), ovines (including sheep), caprines (including goats), avines (including birds such as poultry), cervines (including deer), porcines (including pigs), reptilians (including reptiles), and piscines (including fish).
- compositions of the invention can be used as feed additive to help animals (such as production animals) gain weight faster.
- the compositions can serve as an alternative to antibiotics intended for weight gain and growth promotion in production animals.
- the animal in such versions can comprise any production animal, such as bovines (including cattle), ovines (including sheep), caprines (including goats), avines (including birds such as poultry), cervines (including deer), porcines (including pigs), reptilians (including reptiles), piscines (including fish), or any other production animal.
- the composition is administered in an amount effective to increase feed conversion rate in the animal relative to a control animal not receiving the composition.
- the composition is administered in an amount effective to decrease serum levels of a pro-inflammatory cytokine in the animal relative to a control animal not receiving the composition.
- pro-inflammatory cytokines include IL-2, IL-8, IL-6, IL-7, IL-15, IL-18, MCP-1, TNF ⁇ , and IL-1-beta.
- Some versions of the invention comprise a mixture comprising free tetrahydrocurcuminoid (uncomplexed tetrahydrocurcuminoid) and free zinc (uncomplexed zinc) in the form of a dry powder.
- the free tetrahydrocurcuminoid can comprise tetrahydrocurcumin.
- the mixture can be made without the use of a solvent.
- the mixture can be administered to an animal directly in powder form or mixed with a carrier before administering.
- the mixture can also or alternatively be solubilized in a solvent as described herein to permit complexation of the tetrahydrocurcuminoid and the zinc.
- the tetrahydrocurcuminoid and the zinc can be present in the mixture in a ratio from 0.001:1 (tetrahydrocurcuminoid:zinc) to 1000:1 (tetrahydrocurcuminoid:zinc), such as a ratio from 0.01:1 (tetrahydrocurcuminoid:zinc) to 100:1 (tetrahydrocurcuminoid:zinc).
- Some versions of the invention comprise a mixture comprising free tetrahydrocurcuminoid (uncomplexed tetrahydrocurcuminoid), free curcuminoid (uncomplexed curcuminoid), and free zinc (uncomplexed zinc) in the form of a dry powder.
- the free tetrahydrocurcuminoid can comprise tetrahydrocurcumin.
- the free curcuminoid can comprise curcumin.
- the mixture can be made without the use of a solvent.
- the mixture can be administered to an animal directly in powder form or mixed with a carrier before administering.
- the mixture can also or alternatively be solubilized in a solvent as described herein to permit complexation of the tetrahydrocurcuminoid, the curcuminoid, and the zinc.
- the tetrahydrocurcuminoid and the zinc can be present in the mixture in a ratio from 0.001:1 (tetrahydrocurcuminoid:zinc) to 1000:1 (tetrahydrocurcuminoid:zinc), such as a ratio from 0.01:1 (tetrahydrocurcuminoid:zinc) to 100:1 (tetrahydrocurcuminoid:zinc);
- the zinc and curcuminoid can be present in a ratio from 0.001:1 (zinc:curcuminoid) to 1000:1 (zinc:curcuminoid), such as a ratio from 0.01:1 (zinc:curcuminoid) to 100:1 (zinc:curcuminoid); and/or the tetrahydrocurcumi
- Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
- tetrahydrocurcumin was solvated in anhydrous ethanol and placed into a beaker.
- zinc chloride was solvated in anhydrous ethanol and placed into the same beaker.
- a stir bar was added, and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-tetrahydrocurcumin complex.
- the mixture was placed into a rotoevaporator flask, and the ethanol was removed.
- the tetrahydrocurcumin-zinc-tetrahydrocurcumin complex was placed into a Buchner funnel and thoroughly washed with water to remove unreacted components. The washed complex was dried at 50° C. until a dry powder was formed.
- the complex was analyzed for zinc content to quantify the amount of zinc in the complex. It was found that 23% of the starting zinc remained in the dried tetrahydrocurcumin powder, consistent with zinc being bound by chelation bonds to tetrahydrocurcumin.
- tetrahydrocurcumin was solvated in propylene glycol and placed into a beaker.
- One mole of zinc chloride was solvated in water and placed into the same beaker.
- the propylene glycol:water ratio was 1:1.
- a stir bar was added and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-tetrahydrocurcumin complex.
- the tetrahydrocurcumin-zinc-tetrahydrocurcumin complex was placed into a Buchner funnel and washed with water to remove unreacted components. The washed complex was dried at 50° C. until a dry powder was formed.
- the complex was analyzed for zinc content to quantify the amount of zinc in the complex.
- 0.25 moles of tetrahydrocurcumin and 0.75 moles of curcumin were solvated in methanol to create 1 mole of ligand and placed in a beaker.
- One mole of zinc acetate anhydrous was solvated in methanol and added to the beaker to give a 1:1 molar ratio of ligand:metal.
- a stir bar was added, and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-curcumin complex.
- the mixture was placed into a rotary evaporator flask, and the methanol was removed.
- the tetrahydrocurcumin-zinc-curcumin complex was placed into a Buchner funnel and washed with water to remove unreacted components. The washed complex was dried at 50° C. until a dry powder was formed. The complex was analyzed for zinc content to quantify the amount of zinc in the complex. UV and FTIR analysis showed characteristic changes in profiles compared to the control material of methanol-solvated tetrahydrocurcumin and curcumin mixture.
- tetrahydrocurcumin and 1 mole of curcumin were solvated in methanol to create 2 moles of ligand and placed in a beaker.
- One mole of zinc acetate anhydrous was solvated in methanol and added to the beaker to give a 2:1 molar ratio of ligand:metal.
- a stir bar was added, and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-curcumin complex.
- the mixture was placed into a rotary evaporator flask, and the methanol was removed.
- the complex of tetrahydrocurcumin-zinc-curcumin was placed into a Buchner funnel and washed with water to remove unreacted components. The washed complex was dried at 50° C. until a dry powder was formed. The complex was analyzed for zinc content to quantify the amount of zinc in the complex. UV and FTIR analysis showed characteristic changes in profiles compared to the control material of methanol-solvated tetrahydrocurcumin and curcumin mixture.
- tetrahydrocurcumin and 1 mole of curcumin were solvated in methanol to create 2 moles of ligand and placed in a beaker.
- One mole of zinc chloride was solvated in methanol and added to the beaker to give a 2:1 molar ratio of ligand:metal.
- a stir bar was added, and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-curcumin complex. It was noted that the component mixture turned from an initial yellow color at time zero into a red color by 2 hours as it became a complex.
- a change from yellow color to a red color is consistent with molecular changes to curcumin as zinc binds to it due to structural chromophore changes.
- the complex was placed into a rotoevaporator flask, and the methanol was removed to result in a red color powder matrix complex.
- FIGS. 5A and B show a shift of the peak at 283 nm in the UV profile for the control material ( FIG. 5A ) to 286 nm for the pH 2.0 complex ( FIG. 5B ).
- FTIR profiles of the pH 2.0 tetrahydrocurcumin-zinc complex also revealed changes at 3397, 970, and 450 wavenumbers ( FIGS. 6A and 6B ). These changes are consistent with zinc binding to tetrahydrocurcumin and changing the structural conformation when complexation occurs. It is concluded that both the UV and the FTIR profile are consistent with zinc binding to tetrahydrocurcumin and causing a complexation reaction and the formation of a new molecule.
- FIGS. 5A and 5B show a shift of the peak at 283 nm in the UV profile for the control material ( FIG. 5A ) to 286 nm for the pH 2.0 complex ( FIG. 5B ). This shift further increased to 292 nm with the pH 7.5 tetrahydrocurcumin-Zn complex material, and a broadening of the lagging side peak occurred ( FIG. 5C ).
- FTIR profiles of the pH 2.0 tetrahydrocurcumin-Zn complex revealed changes at 3397, 970, and 450 wavenumbers ( FIGS. 6A and 6B ). These changes are consistent with zinc binding to tetrahydrocurcumin and changing the structural conformation when complexation occurs.
- FTIR profiles of the pH 7.5 tetrahydrocurcumin-Zn complex revealed changes at 1576, 1426, and 2980 wavenumbers as compared to the starting tetrahydrocurcumin material (FIGS. FIGS. 6A and 6C ). These changes are consistent with binding of zinc to hydroxyl groups in the central part of the structure and thus changing the structure of tetrahydrocurcumin. It is concluded that both the UV and the FTIR profiles are consistent with zinc binding to tetrahydrocurcumin and causing a complexation reaction and the formation of a new molecule.
- tetrahydrocurcumin has some different biological properties than curcumin
- having different ratios of tetrahydrocurcumin to curcumin in the zinc complex of the invention can extend the efficacy of the invention for different disease and health conditions.
- the ratio of tetrahydrocurcumin to curcumin during complexation to zinc was examined.
- the pH during the complexation reaction was examined at acidic and at neutral pH. Ratios of 25:75, 50:50, and 75:25 of tetrahyrdocurcumin:curcumin were created by weighing out relative amounts tetrahydrocurcumin and curcumin based on molecular weights of each and mixing together to form a uniform powder.
- a 2-mole amount of the uniform mixed ratios of tetrahydrocurcumin:curcumin were added to a 1-mole amount of zinc chloride.
- One liter of methanol was added to solvate the mixture, and the pH was noted to be pH 4.0.
- Half of the solvated solution was removed to a different beaker, and the pH was raised to pH 7.0 using triethylamine. Raising the pH from pH 4 to pH 7 changed the color from a yellow/orange to red. All 6 sets of the mixed ratio solutions were stirred at room temperature for 24 hours.
- the solutions were dried to a powder by rotoevaporation and subjected to UV and FTIR analysis.
- the 250 mg of dried powders were dissolved in 1 ml acetone and were subsequently purified using Sephadex G-10 low pressure chromatography with a 45:55 acetone:water solvent to separate the complexed powders based on molecular weight. Absorbance at OD 425 and pH were monitored for the eluted fractions ( FIGS. 7A-7F ). Different color bands migrated through the column that corresponded to different molecular weights. The leading edge of the pH 7.0 complexes were dark red while lagging subsequent fractions were yellow/orange. The pH of fractions decreased with a corresponding increase of OD 425 that recovered as less OD was eluting ( FIGS. 7A-7F ).
- the UV and FTIR of purified fractions are consistent with the formation of a novel molecular complex of tetrahydrocurcumin and curcumin concurrently bound to zinc.
- Different ratios of curcumin to tetrahydrocurcumin can be utilized when binding to zinc. Raising the pH of the reaction from acidic conditions to neutral conditions allows for the change of the predominant keto forms of the reactants to an enol form. This change unexpectedly allows for more efficient binding of the diavalent zinc concurrently to both curcumin and tetrahydrocurcumin with subsequent greater changes observed in UV and FTIR profiles.
- curcumin, curcumin-Zn complex, tetrahydrocurcumin, tetrahydrocurcumin-Zn complex, and tetrahydrocurcumin-Zn-curcumin complex were solubilized in saline with 5.0% DMSO, and 1 ml was placed in the top wells and incubated for 2 hours at 37° C.
- OD 425 nm and OD 220 nm were measured in the top and bottom wells spectrophotometrically or by HPLC.
- OD 425 nm is representative of curcumin, curcumin-Zn complexes, and tetrahydrocurcumin-Zn-curcumin complexes.
- OD 220 nm is representative of tetrahydrocurcumin and tetrahydrocurcumin-Zn complexes.
- the % net uptake of the respective agents were calculated by summing the OD in the upper and lower wells and then dividing the sum by the bottom well OD and graphed as shown in FIG. 10A .
- the data indicate that zinc improved the uptake of tetrahydrocurcumin by >2 fold.
- a similar amount of uptake was observed in the tetrahydrocurcumin-Zn-curcumin complex as compared to the tetrahydrocurcumin-Zn complex.
- the data indicate in this particular cell culture system that some curcumin crossed membranes, with or without the presence of zinc.
- the blood was allowed to clot and the plasma was removed by centrifugation for subsequent baseline analysis.
- the chickens were allowed to rest overnight.
- the contents of each of the respective syringes were then administered to separate chickens via the mouth, ensuring that the contents were consumed.
- Blood was removed at 2, 4, and 24 hours from each bird and allowed to clot.
- the recovered serum was mixed with equal volumes of acetone via vortexing for 30 seconds and then centrifuged to remove proteins in the pellet while recovering curcumin, tetrahydrocurcumin, or the elements of the tetrahydrocurcumin-Zn-curcumin complex in the supernatant.
- the supernatants from each time point were analyzed by standard HPLC methods for the presence of curcumin, tetrahydrocurcumin, or the tetrahydrocurcumin-Zn-curcumin complex at 280 nm and 425 nm wavelengths.
- the results show that peaks due to curcumin, tetrahydrocurcumin, or the tetrahydrocurcumin-Zn-curcumin complex could be seen at the 2-hour, 4-hour, and 24-hour timepoints in each of the respective samples.
- the tetrahydrocurcumin-Zn-curcumin complex had 2 to 3 times as much peak area at the 1.996 min chromatogram retention peak as curcumin or tetrahydrocurcumin for the 2-hour timepoint ( FIG. 11 ). This result is consistent with an increased bioavailability of the tetrahydrocurcumin-Zn-curcumin of the invention in an animal by 2 hours as compared to just curcumin or tetrahydrocurcumin.
- the data show that the tetrahydrocurcumin-Zn-curcumin complex is metabolized over time as evidenced by the disappearance of HPLC peaks and the appearance of new HPLC peaks in the serum at 24 hours, as seen in chromatograms analyzed at 280 nm ( FIGS. 12A-12C ) and 425 nm ( FIGS. 13A-13C ).
- This unexpected result is consistent with an increased bioavailability and increased longevity of the tetrahydrocurcumin-Zn-curcumin complex of the invention in blood not seen with curcumin alone or tetrahydrocurcumin alone.
- the data also show acute safety of the invention at 1 g/lb. body weight, as the 5-lb birds did not die nor show any ill effects when orally ingesting 1 gram of the invention.
- a live animal trial was conducted to determine the effects of a tetrahydrocurcumin-Zn-curcumin complex to improve health. Increased weight gain in newborn chickens receiving the tetrahydrocurcumin-Zn-curcumin complex as compared to control newborn chickens that did not receive the tetrahydrocurcumin-Zn-curcumin complex in the same time frame is a measure of improved health and efficacy of the invention.
- the tetrahydrocurcumin-Zn-curcumin complex used in the trial was the powder created by mixing 75% curcumin with 25% tetrahydrocurcumin and complexed with zinc chloride in a 2:1 molar ratio as described in Example 9.
- the feed used throughout the trial was standard poultry feed mash to ensure uniform mixing of the invention. Chickens were weighed on weekly basis and the amount of feed consumed was recorded. Results are shown in FIG. 14A .
- the feed conversion ratio was calculated on a weekly basis for the different groups for the amount of feed consumed relative to the amount of weight gain.
- the averages of the weekly FCRs for the entire trial from week 0 to week 6 are reported in graph FIG. 14B .
- the data indicate that birds receiving 0.5% of the tetrahydrocurcumin-Zn-curcumin complex in feed had a lower and thus better FCR than the control group over the course of the trial.
- the group receiving 1.0% of the tetrahydrocurcumin-Zn-curcumin complex had a lower and even better FCR than the 0.5% group.
- the results of the feed trial with the use of the tetrahydrocurcumin-Zn-curcumin complex indicate the efficacy of the invention for improving weight gain in chicken in a statistically significant manner.
- weight-gain in chickens is related to overall health
- these data are consistent with the complexes of the invention to improve overall health in animals.
- the data are consistent with the complexes of the invention reducing oxidative stress and modifying the gut microbiome in a favorable manner that allows for improved FCR in chickens or other animals.
- the data also show favorable chronic use safety of the invention, as no birds died or showed any ill effects as result of ingesting the composition on a daily basis for 6 weeks fed at approximately 5 g/lb. body weight. This is about 100 ⁇ the fed level seen in humans for curcumin of 0.05 g/lb. body weight for safe chronic ingestion, thus indicating safety of chronic consumption of the invention.
- cytokines in serum have been used as a measure of general health in animals.
- a live animal trial was conducted to determine the effects of a tetrahydrocurcumin-zinc-curcumin complex on cytokine levels in serum.
- the cytokines of interleukin 1-beta (IL-1-beta), interleukin 6 (IL-6), interleukin 10 (IL-10), and interferon gamma were measured at the end of a 6-week period in newborn chickens receiving the tetrahydrocurcumin-zinc-curcumin complex on a daily basis as compared to control newborn chickens that did not receive the tetrahydrocurcumin-zinc-curcumin complex in the same time frame.
- the trial was conducted over a 6-week period and was part of the weight gain trial described above in Example 12.
- One chicken group served as a control, one group received 0.5% w/w of the tetrahydrocurcumin-zinc-curcumin complex mixed into the feed, and another group received 1.0% of the tetrahydrocurcumin-zinc-curcumin complex mixed into the feed.
- the tetrahydrocurcumin-zinc-curcumin complex used in the trial was a powder created by mixing 75% curcumin with 25% tetrahydrocurcumin and complexed with zinc chloride in a 2:1 molar ratio as described in Example 9.
- the feed used throughout the trial was standard poultry feed mash to ensure uniform mixing of the invention.
- FIGS. 15A-15D administration of the tetrahydrocurcumin-zinc-curcumin complex reduced the amount of IL-1-beta ( FIG. 15A ) and IL-6 ( FIG. 15B ) circulating in the blood of the chickens but did not affect the amounts of IL-10 ( FIG. 15C ) or interferon gamma ( FIG. 15D ).
- interferon gamma and IL-10 levels tend to be elevated if viral diseases are present. Because no obvious viral diseases were present in these birds at the beginning and throughout the trial, it is not surprising that administration of tetrahydrocurcumin-zinc-curcumin complex did not alter the levels of these cytokines.
- the antioxidant activity of a tetrahydrocurcumin-Zn-curcumin complex of the invention was measured and compared to curcumin and tetrahydrocurcumin.
- a standard DPPH (2,2-diphenyl-1-picryl-hydrazyl-hydrate) antioxidant assay was used to predict antioxidant activities, for example, by mechanisms in which antioxidants act to inhibit lipid oxidation.
- the assay scavenges the DPPH radical and therefore determines free radical scavenging capacity of test subjects.
- the test subjects were administered the tetrahydrocurcumin-Zn-curcumin, curcumin, or tetrahydrocurcumin.
- the DPPH free radical method is an antioxidant assay based on electron-transfer that produces a violet solution in ethanol.
- DPPH is a free radical that is stable at room temperature and is reduced in the presence of an antioxidant molecule to give rise to a yellow colored product, diphenylpicryl hydrazine, in ethanol solution.
- DPPH free radical scavenging is an accepted mechanism for screening the antioxidant activity. The method is widely used due to relatively short time required for the analysis.
- a tetrahydrocurcumin-Zn-curcumin complex of the invention was examined for its ability to influence cytokine release in a cell culture system.
- Cytokine release leads to systemic inflammatory syndromes involving elevated levels of circulating cytokines and immune-cell hyperactivation.
- the cytokine release can be triggered by various stresses, viral pathogens like Covid-19, cancers, autoimmune conditions, and monogenic disorders.
- lipopolysaccharide (LPS) is commonly used as stressor to induce cytokine release.
- MDCK cells were cultured in a DMEM media supplemented with FBS and antibiotic and were maintained in a humidified atmosphere of 5% CO 2 and 95% humidity. Almost 70% confluent cells were treated with different concentrations of tetrahydrocurcumin-Zn-curcumin, curcumin, or tetrahydrocurcumin (0.125, 0.25, 0.5, or 1 mg/ml) in plates containing 3 mL of DMEM.
- the tetrahydrocurcumin-Zn-curcumin was made as described in Example 9.
- the curcumin controls and tetrahydrocurcumin controls were from the same starting material used to make the tetrahydrocurcumin-Zn-curcumin.
- FIGS. 17A-17I show lipopolysaccharide (LPS)-stimulated cytokine release in the absence or presence of tetrahydrocurcumin-Zn-curcumin (data were analyzed using GraphPad Prism).
- LPS stimulated cytokine release over the baseline levels in all cases, except for GM-CSF where the baseline level was zero to begin with.
- Tetrahydrocurcumin-Zn-curcumin consistently reduced the LPS-stimulated cytokine levels to below baseline levels in a dose-dependent manner.
- tetrahydrocurcumin-Zn-curcumin stimulated the release of this particular cytokine.
- Cytokines are a diverse group of small proteins that are secreted by cells for the purpose of intercellular signaling, and many, but not all, are associated with pro-inflammatory reactions in the body. Reducing cytokine release from stressed cells or enhancing certain cytokines is important for maintaining the overall health of a human or animal.
- IL-2 promotes inflammatory responses and functions to stimulate T-cell growth in asthma, atopic dermatitis, auto immune diseases, cancer and inflammatory bowel disease.
- the reduction in IL-2 resulting from administration with the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to overall health to an individual with these conditions.
- IL-8 plays a pro-inflammatory role as a chemoattractant recruitment of neutrophils.
- Babesia parasite infection in dogs causes increased level of IL-8.
- the reduction in IL-8 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to animals with this parasite infection.
- IL-6 is associated with pro-inflammatory responses and responsible for many inflammatory diseases in both humans and animals.
- synovial fluid of dogs with cranial cruciate ligament rupture have high level of IL-6 that may results in arthritic symptoms.
- IL-6 may be involved in the pathogenesis of tubule-glomeruli injury and subclinical ehrlichiosis may lead in chronic kidney disease in dogs.
- the reduction of IL-6 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals suffering from arthritis or other diseases.
- IL-7 causes cartilage matrix degradation that may results in joint destruction.
- High expression of IL-7 causes bone destruction in dogs.
- IL-7 is overexpressed during viral infection in dogs.
- the reduction of IL-7 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals suffering from arthritis or other diseases.
- IL-15 is a pro-inflammatory cytokine that is expressed in several inflammatory disorders, including rheumatoid arthritis, psoriasis, and pulmonary inflammatory diseases.
- IL-15 and IL-18 are elevated in pyometra disease in dogs. Pyometra is caused by bacterial infection of the uterus and can result in systemic inflammatory response syndrome.
- the reduction of IL-15 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals with these or similar health conditions.
- IL-18 has been implicated in several autoimmune diseases, myocardial function, metabolic syndromes, psoriasis, inflammatory bowel disease, hemophagocytic syndromes, macrophage activation syndrome, sepsis, mental cognition issues, and acute kidney injury.
- IL-18 is highly expressed in dogs with metaphyseal osteopathy (an inflammatory bone disease). the reduction of IL-18 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals with these health conditions.
- Monocyte chemoattractant protein-1 (MCP-1) is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages to produce inflammation. Babesia infection in dogs causes increased level of MCP-1 and further inflammation. The reduction of MCP-1 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals with these health conditions.
- TNF- ⁇ is responsible for range of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis. TNF- ⁇ is noticeably up-regulated in dogs with visceral leishmaniasis disease and chronic kidney disease, and thus considered as a key factor for the initiation, maintenance, and persistence of inflammation. A reduction of TNF- ⁇ resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals with these health conditions
- Granulocyte-macrophage colony stimulating factor stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes.
- GM-CSF improves intestinal barrier integrity by augmenting innate immune responses.
- Acutely increased GM-CSF levels resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, for immunity and improving health in humans and animals.
- tetrahydrocurcumin-Zn-curcumin of the invention for reducing pro-inflammatory cytokines or augmenting levels of beneficial cytokines.
- the tetrahydrocurcuminoid-metal complexes can be administered to animals to increase animal health, reduce stress, reduce oxidative stress, maintain health, improve health, improve immunity, improve vaccination efficacy, increase feed conversion rate, and/or decrease pro-inflammatory cytokine levels in an animal.
- tetrahydrocurcumin 0.25 moles of tetrahydrocurcumin and 0.75 moles of curcumin were mixed together to create 1 mole of ligand as a dry powder and placed in a beaker.
- One mole of zinc chloride was added to the beaker to give a 1:1 molar ratio of ligand:metal and mixed to form a dry powder mixture of tetrahydrocurcumin, curcumin, and zinc chloride.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Pediatric Medicine (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Abstract
Description
- The present invention is directed to tetrahydrocurcuminoid-metal complexes and uses of same for maintaining and improving health and/or boosting immunity in animals.
- Many health issues can be improved by supporting and having a healthy immune system. On the whole, the immune system does a remarkable job of defending against disease-causing microorganisms and other sources of stress on the immune system. Bacteria and flu viruses are sources of disease but less obvious sources of stress on the immune system include simply being old, or traveling or having emotional issues can be also be a source of stress. As good as the immune system is, it sometimes fails, a germ invades successfully, and sickness occurs. An underlying aspect to how all these sources of stress affect the body is oxidative stress from reactive oxygen species. Various infective agents can cause the production of free radicals and oxidative stress that, in turn, causes problems for cells, and this damage can spread throughout the body. For example, oxygen free radicals can react with cellular components to damage cells membranes, proteins, and DNA. Antioxidants combat the free radicals by donating an electron to the free radical of reactive oxygen species. Antioxidants are molecules that prevent free radicals from taking electrons and causing cellular damage. Antioxidants are able to give an electron to a free radical without becoming destabilized themselves because they are inherently stable without having a complete electron valence shell. As such, antioxidants can stop free radical chain reactions and limit the damage to the body. The body has some inherent antioxidants such as glutathione, but obtaining antioxidants from the diet or supplements can help reduce oxidative stress and help the immune system. Once the balance between the accumulation of reactive oxidative species and the removal of oxides is broken, oxidative stress is established. The ultimate consequences of this oxidative stress include tissue damage, inflammation responses, and cell death.
- A strategy to improve general health would be to help reduce oxidative stress and also help the immune system in other more specific ways. The challenge is then to find antioxidants that can also boost the immune system.
- The invention is directed in part to tetrahydrocurcuminoid-metal complexes. The tetrahydrocurcuminoid-metal complexes are complexes comprising at least one tetrahydrocurcuminoid chelated to a metal. The tetrahydrocurcuminoid-metal complexes of the invention encompass tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes and tetrahydrocurcuminoid-metal-curcuminoid complexes. The metal can be zinc or other metals. The molecular complex can be combined with additional interferon boosting nutraceuticals, such as Spirulina extracts, lipoic acid, ferulic acid, N-acetyl cysteine, or other nutraceuticals.
- The tetrahydrocurcuminoid-metal complexes can be orally or topically delivered to animals for the purpose of stimulating the immune system in times of stress from diseases or other causes of stress to help maintain general health. Exemplary animals include mammals, fish, birds, and reptiles.
- The invention helps animals achieve better overall health, especially in times of oxidative stress, such as from diseases or to maintain optimum immunity health on a daily basis. The tetrahydrocurcuminoid-metal complex compositions can be combined with other immune modulating agents to further enhance bioavailability and antioxidant capability to achieve optimal health.
- The invention in some aspects encompasses a chelation of zinc or other metals to a tetrahydrocurcuminoid and a curcuminoid simultaneously.
- The molecular complex of the invention further advances the art of stimulating the immune system by providing both tetrahydrocurcuminoids with curcuminoids orally or topically instead of relying on the body to metabolize curcuminoids into tetrahydrocurcuminoids, as tetrahydrocurcuminoids are not found in turmeric extracts. As certain curcuminoids and tetrahydrocurcuminoids have distinct benefits over one and another, the invention further advances the art by taking the advantages of both. The invention further advances the art by creating molecular tetrahydrocurcuminoid-metal-curcuminoid complexes that synergistically increase the antioxidant and immune stimulating capability of both tetrahydrocurcuminoids, such as tetrahydrocurcumin, and curcuminoids, such as curcumin. By having a synergistic capability, relatively less amount of the novel molecule of the invention is required to achieve the same efficacy for anti-oxidative, anti-inflammatory, and immune boosting aspects compared to the individual components of tetrahydrocurcuminoids, curcuminoids, and metals such as zinc. This allows for an even safer use of curcuminoids, tetrahydrocurcuminoids, and zinc and alleviates toxicity issues that might be possible when higher doses of these individual types of molecules have been used.
- The objects and advantages of the invention will appear more fully from the following detailed description of the preferred embodiment of the invention made in conjunction with the accompanying drawings.
-
FIG. 1 . Exemplary curcumin-metal complex structures. -
FIG. 2 . Structure of an exemplary curcumin-metal-curcumin complex. -
FIG. 3 . Structure of an exemplary tetrahydrocurcumin-metal-curcumin complex of the invention. -
FIG. 4 . 3D model structures of an exemplary tetrahydrocurcumin-metal-curcumin complex of the invention. -
FIGS. 5A-5C . UV profiles of tetrahydrocurcumin (FIG. 5A ), a tetrahydrocurcumin-Zn complex of the invention created at pH 2 (FIG. 5B ), and a tetrahydrocurcumin-Zn complex of the invention created at pH 7.5 (FIG. 5C ). -
FIG. 6 . FTIR profiles of tetrahydrocurcumin (FIG. 6A ), a tetrahydrocurcumin-Zn complex of the invention created at pH 2 (FIG. 6B ), and a tetrahydrocurcumin-Zn complex of the invention created at pH 7.5 (FIG. 6C ). -
FIGS. 7A-7F . Sephadex G-10 purification of different ratios of curcumin:tetrahydrocurcumin (THC) when complexed with zinc at pH 4.0 (FIGS. 7A, 7C, and 7E ) or pH 7.0 (FIGS. 7B, 7D, and 7F ). -
FIGS. 8A and 8B . UV profiles of Sephadex G10-purified red-colored (FIG. 8A ) and yellow/white-colored (FIG. 8B ) zinc complexes of curcumin and tetrahydrocurcumin generated with a 25:75 curcumin:tetrahydrocurcumin ratio. -
FIGS. 9A and 9B . FTIR profiles of Sephadex G1-purified red-colored (FIG. 9A ) and yellow/white-colored (FIG. 9B ) zinc complexes of curcumin and tetrahydrocurcumin generated with a 25:75 curcumin:tetrahydrocurcumin ratio. -
FIGS. 10A and 10B . % net uptake of tetrahydrocurcumin (THC) and zinc complexes thereof (FIG. 10A ) and curcumin and zinc complexes thereof (FIG. 10B ) across IPEC-J2 cell membranes as determined by HPLC. -
FIG. 11 . Time course of bioavailability in blood of curcumin, tetrahydrocurcumin (THC), and a THC-zinc-curcumin complex. -
FIGS. 12A-12C . HPLC at 280 nm of serum of chickens fed curcumin (FIG. 12A ), tetrahydrocurcumin-zinc-curcumin complex (THC-Zn-Curcumin) (FIG. 12B ), and tetrahydrocurcumin (THC) (FIG. 12C ) at 2-hour, 4-hour, and 24-hour timepoints after feeding. -
FIGS. 13A-13C . HPLC at 425 nm of serum of chickens fed curcumin (FIG. 13A ), tetrahydrocurcumin-zinc-curcumin complex (THC-Zn-Curcumin) (FIG. 13B ), and tetrahydrocurcumin (THC) (FIG. 13C ) at 2-hour, 4-hour, and 24-hour timepoints after feeding. -
FIGS. 14A and 14B . Average weights (FIG. 14A ) and average feed conversion rates (FIG. 14B ) of chickens fed 0% w/w, 0.5% w/w, or 1% w/w of tetrahydrocurcumin-zinc-curcumin complex for six weeks. -
FIGS. 15A-15D . Levels of IL-1-beta (FIG. 15A ), IL-6 (FIG. 15B ), IL-10 (FIG. 15C ), and interferon gamma (FIG. 15D ) in chickens fed 0% w/w, 0.5% w/w, or 1% w/w of tetrahydrocurcumin-zinc-curcumin complex for six weeks. -
FIG. 16 . Antioxidant activity of curcumin (0.125 mg/ml, 0.25, mg/ml, 0.5 mg/ml), tetrahydrocurcumin (THC) (0.125 mg/ml, 0.25, mg/ml, 0.5 mg/ml), and tetrahydrocurcumin (THC)-Zn-curcumin (0.125 mg/ml, 0.25, mg/ml, 0.5 mg/ml) as determined by DPPH (2,2-diphenyl-1-picryl-hydrazyl-hydrate) antioxidant assay. -
FIGS. 17A-17I . Release of indicated cytokines from MDCK cells not stimulated with lipopolysaccharide (LPS) (−); stimulated with LPS (8 μg/ml) in the absence of tetrahydrocurcumin-Zn-curcumin (+); stimulated with LPS (8 μg/ml) in the presence of 0.125 mg/ml tetrahydrocurcumin-Zn-curcumin (0.125T+L), 0.25 mg/ml tetrahydrocurcumin-Zn-curcumin (0.25T+L), 0.5 mg/ml tetrahydrocurcumin-Zn-curcumin (0.5T+L), or 1 mg/ml tetrahydrocurcumin-Zn-curcumin (1T+L); or treated with 0.125 mg/ml tetrahydrocurcumin-Zn-curcumin (0.125T), 0.25 mg/ml tetrahydrocurcumin-Zn-curcumin (0.25T), or 0.5 mg/ml tetrahydrocurcumin-Zn-curcumin (0.5T) without stimulation with LPS, as indicated. - The invention in some aspects is directed to complexes comprising at least one tetrahydrocurcuminoid chelated to a metal (tetrahydrocurcuminoid-metal complexes). Chelation is a type of chemical bonding of ions and molecules to metal ions. It involves the formation or presence of two or more separate coordinate bonds between a polydentate (multiple bonded) ligand and a single central atom. The ionic form of the central atom can be critical to the success of chelation to the ligand, as divalent ions and trivalent ions do not always bind in the same manner. Various zinc forms can be utilized in the invention including zinc chloride, zinc acetate, zinc gluconate, zinc sulfate, zinc picolinate in anhydrous or hydrated formats. Other ionic metals can be used including iron, copper, cadmium, and iridium in the chelation bonding mechanism.
- Certain metals have been found to boost the immune system. Zinc is one such metal of a divalent nature. Zinc is essential for multiple cellular functions including immunity. Zinc is essential for normal development and function of cell-mediating innate immunity, neutrophils, and natural killer cell. Beneficial therapeutic response of zinc supplementation has been observed in the diarrhea of children, chronic hepatitis C, shigellosis, leprosy, tuberculosis, pneumonia, acute lower respiratory tract infection, common cold, and leishmaniasis. Zinc supplementation has been shown to be effective in decreasing incidences of infections in the elderly and patients with sickle cell disease and in decreasing incidences of respiratory tract infections in children. Zinc supplementation has prevented blindness in 25% of the elderly individuals with dry type of macular disorder. Zinc supplementation has been shown to be effective in decreasing oxidative stress and pro-inflammatory cytokines such as TNF-α and IL-1b in elderly individuals and patients. Zinc supplementation has been successfully used as a therapeutic and preventive agent for many conditions.
- Zinc is considered to be relatively nontoxic, particularly if taken orally. However, manifestations of overt toxicity symptoms (nausea, vomiting, epigastric pain, lethargy, and fatigue) will occur with extremely high zinc intakes. Even lower levels of zinc supplementation, closer in amount to the recommended daily allowance (RDA), have been suggested to interfere with the utilization of copper and iron and to adversely affect HDL cholesterol concentrations. Individuals using zinc supplements should be aware of the possible complications attendant to their use. (Fosmire). As such, it is desirable to get the benefits of zinc in as low a dose as possible.
- Besides metals like zinc that help the immune system, various nutraceuticals have been used to reduce oxidative stress. While there are many antioxidants available, ones from natural sources are of interest from a general safety point of view, provided certain stability problems can be overcome. One such natural antioxidant that can be used is curcumin, from the turmeric plant (Curcumin longa). Turmeric has been widely used as a spice in Indian food for thousands of years and contains a variety of constituents including curcuminoids such as curcumin, demethoxycurcumin and bisdemethoxycurcumin. Curcumin is the most widely known of these curcuminoids and is a naturally occurring polyphenolic phytoconstituent, isolated from turmeric rhizomes with uses as natural yellow colorant along with its use a spice in food. Curcumin also has many health benefits ranging from its anti-inflammatory actions in joints as an oxidative stress reducer to its anti-viral actions. Curcumin and curcuminoids interfere with the activity of a protein in the viruses used to invade the host cells. By doing so, the curcumin and curcuminoids prevent replications of the virus. Curcumin can reduce viral replication by over 90 percent in laboratory cells infected with influenza varieties. Curcumin decreases viral replication in infected cells, but also seems to protect other cells from becoming infected. Curcumin can also boost beta interferon levels reduce oxidative stress during influenza (Dai).
- However, there are practical problems associated with using curcumin for boosting the immune system. Curcumin is insoluble in water under acidic or neutral conditions. Curcumin is unstable by undergoing rapid hydrolytic degradation in neutral or alkaline conditions. Since it is insoluble in aqueous medium and has poor stability towards oxidation, light, alkalinity, enzymes and heat, curcumin cannot really be widely used in pharmaceutical preparations unless stability issues can be overcome.
- Turmeric and extracts with curcuminoids are considered safe when taken orally and when used topically by most people. Turmeric products that provide up to 8 grams of curcumin daily appear to be safe when used for up to 2 months (e.g., 0.05 g curcumin/lb. body weight). Turmeric typically does not cause serious side effects. Some people can experience mild side effects such as stomach upset, nausea, dizziness, or diarrhea. These side effects are more common at higher doses. However, under certain health conditions, curcumin can cause problems with people with gallbladder problems, bleeding problems where turmeric might slow blood clotting, in diabetes where curcumin might decrease blood sugar in diabetic people, after surgery where turmeric might slow blood clotting and other possible situations. As such, being able to use less curcumin to achieve its beneficial health effects rather than higher amounts of curcumin is desirable.
- Curcumin is a ligand that forms stable complexes with certain metal ions and nonmetals. In general, stable structures with 1:1, 2:1 and 3:1 (ligand:metal) stoichiometry can occur. Complexation of curcumin with aluminum, copper, or iron has been used for the treatment of Alzheimer's disease and with zinc for increases in vitro antioxidant activity.
- When curcumin is ingested, it is metabolized by cells. One of the major metabolites of curcumin is tetrahydrocurcumin (THC), which lacks the α,β-unsaturated carbonyl moiety and is white in color whereas curcumin is a yellow color. Tetrahydrocurcumin is not found in turmeric plants and has to be metabolized from curcumin by the body. Curcumin and tetrahydrocurcumin exhibit different biological properties. Tetrahydrocurcumin exhibits higher antioxidant activity, whereas curcumin exhibits both pro-oxidant and antioxidant properties. Curcumin appears to bind to and modulate the activities of a wide variety of targets. Tetrahydrocurcumin, however, appears to be a superior antioxidant that lacks both anti-inflammatory and pro-oxidant activities. (Aggarwal). Tetrahydrocurcumin is superior to curcumin for induction of glutathione peroxidase, glutathione-S-transferase, and NADPH: quinone reductase, and the quenching of free radicals. It is possible that curcumin and tetrahydrocurcumin are taken up and metabolized differently in cells, which thus determines their biological activity. However, curcumin offers antiviral capability against the flu. Therefore, if possible, one should use both curcumin and tetrahydrocurcumin to boost the immune system to get advantages of both. However, like curcumin, tetrahydrocurcumin also is not very water soluble. This makes both curcumin and tetrahydrocurcumin poorly bioavailable and problematic for practical uses in readily boosting the immune system in supplements. As such, there is a need to develop methods to increase tetrahydrocurcumin bioavailability and stability.
- The complexation metals to tetrahydrocurcumin has not been explored in any detail for increasing stability, bioavailability, and for boosting the immune system and thus represents a novel solution to these problems. The concurrent complexation of both tetrahydrocurcumin and curcumin to metals has also not been carried out previously. Complexing a metal such as zinc to tetrahydrocurcumin and to curcumin simultaneously therefore represents an advance in the state of the art for the formation of a novel molecular complex. Bonding both curcumin and tetrahydrocurcumin together through a metal bridge by chelation bonding allows for a synergistic increase in their representative efficacies for antioxidant capability and representative immune stimulating capability. This novel complex molecule solves the problems of stability and bioavailability of curcumin and tetrahydrocurcumin and further allows for a single molecule to have the health effects of both curcumin and tetrahydrocurcumin to synergistically occur efficiently.
- When viruses infect cells, one of the immune system's responses is to create interferon that will, in turn, help eliminate viruses. Besides curcumin, certain other nutraceuticals can help boost
type 1 interferon levels in the cell. Elderberry (Sambucus) extracts containing anthocyanins, ferulic acid, N-acetyl cysteine, Spirulina extracts, selenium, lipoic acid, yeast beta glucans, glucosamine are expected to boost induction oftype 1 interferon (McCarty). As an adjunct, these nutraceuticals can complement the activities of the tetrahydrocurcuminoid-metal-curcuminoid complexes of the invention in boosting the immune system or maintaining optimum immunity on a daily basis. - As used herein, “tetrahydrocurcuminoid” refers to a compound having the structure:
- wherein each R1 and R2 are independently selected from the group consisting of H, OH, and OCH3, and salts, esters, tautomers (e.g., enols), and chelates thereof. In some versions, each R1 is independently selected from the group consisting of H and OH. In some versions, each R1 is OH. In some versions, each R2 is selected from the group consisting of H and OCH3. In some versions, each R2 is OCH3. In some versions, each R2 is H. In some versions, one R2 is OCH3, and one R2 is H. Exemplary tetrahydrocurcuminoids include tetrahydrocurcumin, wherein each R1 is OH, and each R2 is OCH3; tetrahydrodemethoxycurcumin, wherein each R1 is OH, one R2 is OCH3, and one R2 is H; and tetrahydrobisdemethoxycurcumin, wherein each R1 is OH, and each R2 is H.
- As used herein, “curcuminoid” refers to a compound having the structure:
- wherein each R1 and R2 are independently selected from the group consisting of H, OH, and OCH3, and salts, esters, tautomers (e.g., enols), and chelates thereof. In some versions, each R1 is independently selected from the group consisting of H and OH. In some versions, each R1 is OH. In some versions, each R2 is selected from the group consisting of H and OCH3. In some versions, each R2 is OCH3. In some versions, each R2 is H. In some versions, one R2 is OCH3, and one R2 is H. Exemplary curcuminoids include curcumin, wherein each R1 is OH, and each R2 is OCH3; demethoxycurcumin, wherein each R1 is OH, one R2 is OCH3, and one R2 is H; and bisdemethoxycurcumin, wherein each R1 is OH, and each R2 is H.
- As used herein, “tetrahydrocurcuminoid-metal complex” refers to a complex comprising at least one tetrahydrocurcuminoid chelated to a metal. Some tetrahydrocurcuminoid-metal complexes of the invention include more than one tetrahydrocurcuminoid chelated to the metal. Some tetrahydrocurcuminoid-metal complexes of the invention include at least one one tetrahydrocurcuminoid chelated to the metal in addition to another compound chelated to the metal. Exemplary tetrahydrocurcuminoid-metal complexes include tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes and tetrahydrocurcuminoid-metal-curcuminoid complexes.
- As used herein, “tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complex” refers to a complex comprising at least two tetrahydrocurcuminoids chelated to a common metal.
- As used herein, “tetrahydrocurcuminoid-metal-curcuminoid complex” refers to a complex comprising at least one tetrahydrocurcuminoid and at least one curcuminoid chelated to a common metal.
- As used herein, “curcuminoid-metal-curcuminoid complex” refers to a complex comprising two curcuminoids chelated to a common metal.
- The metal in the curcuminoid-metal-curcuminoid complexes, tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes, and tetrahydrocurcuminoid-metal-curcuminoid complexes can be a divalent metal or a trivalent metal. Exemplary suitable divalent metals include zinc, copper cadmium, and cobalt. Exemplary suitable trivalent metals include iron, ruthenium, iridium, and aluminum.
- An exemplary structure of a tetrahydrocurcuminoid-metal-curcuminoid complex of the invention is:
- wherein each R1 and R2 are independently selected from the group consisting of H, OH, and OCH3, and salts and esters thereof. In some versions, each R1 is independently selected from the group consisting of H and OH. In some versions, each R1 is OH. In some versions, each R2 is selected from the group consisting of H and OCH3. In some versions, each R2 is OCH3. In some versions, each R2 is H. In some versions, one R2 is OCH3, and three R2 are H. In some versions, two R2 are OCH3, and two R2 are H. In some versions, three R2 are OCH3, and one R2 is H.
- To generate the complexes of the invention, a first ligand (e.g., tetrahydrocurcuminoid) either alone or together with second ligand (e.g., curcuminoid) can be solubilized together or separately in a suitable solvent to generate solubilized ligand. In one example, 0.5 parts by number (e.g., 0.5 mole) of one or more tetrahydrocurcuminoids and 0.5 parts by number (e.g., 0.5 mole) of one or more curcuminoids can be solubilized together in an organic solvent such as methanol, ethanol, glycerol, propylene glycol, or other suitable solvent. This gives 1 part of (e.g., 1 mole) total tetrahydrocurcuminoid/curcuminoid ligand with each ligand in a 1:1 ratio by number. Other relative ratios of tetrahydrocurcuminoid:curcuminoid can be used depending on the requirements of the final product. Exemplary tetrahydrocurcuminoid:curcuminoid ratios (by number) include 100:1, 75:1, 50:1, 25:1, 10:1, 7:1, 3:1, 1:1, 1:3, 1:7, 1:10, 1:25, 1:50, 1:75, and 1:100, any ranges between these exemplary ratios, or any and ratios or ranges above or below these exemplary ratios.
- One part of metal (e.g., zinc) by number (e.g., 1 mole) can then be solubilized in a suitable solvent such as water or organic solvent, depending on the format of the metal.
- The solubilized metal can then be combined with the solubilized ligand, preferably in a 1:1 number ratio of metal to generate a mixed solution. Other ratios of metal can be used. Exemplary metal:ligand ratios (by number) include 100:1, 75:1, 50:1, 25:1, 10:1, 7:1, 3:1, 1:1, 1:3, 1:7, 1:10, 1:25, 1:50, 1:75, and 1:100, any ranges between these exemplary ratios, or any and ratios or ranges above or below these exemplary ratios.
- The mixed solution can optionally have its pH adjusted to a pH from about 6.5 to about 8.5. The pH adjustment can be performed with a reagent such as triethylamine, sodium hydroxide, potassium hydroxide, and/or sodium bicarbonate.
- The combined metal and ligand in the mixed solution can be stirred at room temperature or higher for 2 hours or longer as required for complexation to occur.
- The solvent can then be removed from the complexed composition by filtration or other means, washed in water as required to remove unreacted metal, and further dried to create a powder. Analysis of the complex can be carried to quantify the metal content of the complex. Ultraviolet (UV) and Fourier-transform infrared spectroscopy (FTIR) analysis methods can be used to determine that complexation has occurred by comparing to control ligand.
- The powder can be mixed with other components, such anti-inflammatory agents, immune boosting agents, antioxidants, phytobotanicals, and/or carriers.
- More generally, the methods of making the tetrahydrocurcuminoid-metal complexes of the invention can comprise: solubilizing one or more first compounds in a first solvent to form a first solution, wherein the one or more first compounds comprises a tetrahydrocurcuminoid; solubilizing a metal in a second solvent to form a second solution; mixing the first solution with the second solution to thereby form a mixed solution comprising the one or more first compounds, the metal, and a mixed solvent comprising the first and second solvents; and incubating the mixed solution for a time and a temperature suitable for generating the tetrahydrocurcuminoid-metal complex. In some versions, the one or more first compounds further comprises a curcuminoid. The methods can further comprise: solubilizing one or more third compounds in a third solvent to form a third solution, wherein the one or more third compounds comprises a curcuminoid; and mixing the third solution with the first solution and the second solution to thereby form the mixed solution, wherein the mixed solution comprises the one or more first compounds, the one or more second compounds, the metal, and the mixed solvent comprising the first, second, and third solvents. The methods can further comprise, after the incubating, removing the mixed solvent from the tetrahydrocurcuminoid-metal complex. The methods can further comprise, after the removing, drying the tetrahydrocurcuminoid-metal complex into a powder. The methods can further comprise, prior to or during the incubating, adjusting the pH of the mixed solution to a pH of from 6.5 to 8.5. In some versions, the adjusting comprises adding at least one of triethylamine, sodium hydroxide, potassium hydroxide, and sodium bicarbonate to the mixed solution. In some versions, the incubating is conducted at a pH from 6.5 to 8.5.
- In some versions, the methods of making the tetrahydrocurcuminoid-metal complexes of the invention can comprise incubating one or more first compounds and a metal in a solvent for a time and a temperature suitable for generating the tetrahydrocurcuminoid-metal complex. In some versions, the one or more first compounds comprises a tetrahydrocurcuminoid. In some versions, the one or more first compounds further comprises a curcuminoid. The methods can further comprise, after the incubating, removing the mixed solvent from the tetrahydrocurcuminoid-metal complex. The methods can further comprise, after the removing, drying the tetrahydrocurcuminoid-metal complex into a powder. The methods can further comprise, prior to or during the incubating, adjusting the pH of the mixed solution to a pH of from 6.5 to 8.5. In some versions, the adjusting comprises adding at least one of triethylamine, sodium hydroxide, potassium hydroxide, and sodium bicarbonate to the mixed solution. In some versions, the incubating is conducted at a pH from 6.5 to 8.5. In some versions, the one or more first compounds and the metal are mixed in dry form prior to mixing with the solvent. In some versions, the one or more first compounds and the metal are each added separately in dry form to the solvent.
- The tetrahydrocurcuminoid-metal complexes of the invention can be included in a composition suitable for administration to an animal. The composition can be suitable for oral administration or topical administration. The compositions can be in a solid form, a liquid form, or a semi-solid form (e.g., gel, paste, cream). Exemplary solid forms include powder, tablets, etc.
- The tetrahydrocurcuminoid-metal complexes can be included in the composition in an amount from 0.0000000001% w/w to 99.999999999% w/w. Exemplary amounts include 0.1% w/w, 5% w/w, 10% w/w, 15% w/w, 20% w/w, 25% w/w, 30% w/w, 35% w/w, 40% w/w, 45% w/w, 50% w/w, 55% w/w, 60% w/w, 65% w/w, 70% w/w, 75% w/w, 80% w/w, 85% w/w, 90% w/w, or 95% w/w; any range between these amounts, or any amount or range above or below these amounts.
- In some versions, the composition includes a combination of tetrahydrocurcuminoid-metal-curcuminoid complexes and tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes; tetrahydrocurcuminoid-metal-curcuminoid complexes and curcuminoid-metal-curcuminoid complexes; tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes and curcuminoid-metal-curcuminoid complexes; or tetrahydrocurcuminoid-metal-curcuminoid complexes, tetrahydrocurcuminoid-metal-tetrahydrocurcuminoid complexes, and curcuminoid-metal-curcuminoid complexes. The combination can be included in the composition in an amount from 0.0000000001% w/w to 99.999999999% w/w. Exemplary amounts include 0.1% w/w, 5% w/w, 10% w/w, 15% w/w, 20% w/w, 25% w/w, 30% w/w, 35% w/w, 40% w/w, 45% w/w, 50% w/w, 55% w/w, 60% w/w, 65% w/w, 70% w/w, 75% w/w, 80% w/w, 85% w/w, 90% w/w, or 95% w/w; any range between these amounts, or any amount or range above or below these amounts.
- The composition can include any of a number of additional components, such as inert carriers and/or active ingredients. Each additional component can be included in the composition in an amount from 0.0000000001% w/w to 99.999999999% w/w. Exemplary amounts include 0.1% w/w, 5% w/w, 10% w/w, 15% w/w, 20% w/w, 25% w/w, 30% w/w, 35% w/w, 40% w/w, 45% w/w, 50% w/w, 55% w/w, 60% w/w, 65% w/w, 70% w/w, 75% w/w, 80% w/w, 85% w/w, 90% w/w, or 95% w/w; any range between these amounts, or any amount or range above or below these amounts. “Active ingredients” are ingredients other than the tetrahydrocurcuminoid-metal complexes of the invention having therapeutic or other value when administered to an animal, such as drugs, nutrients, cosmeceuticals, diagnostic agents, nutritional agents, and the like. Exemplary types of active ingredients include anti-inflammatory agents, antioxidants, antimicrobial agents, and immune boosters. Exemplary antioxidants include phytobotanicals, anthocyanins, polyphenols, ferulic acid, N-acetyl cysteine, Spirulina extracts, selenium, lipoic acid, yeast beta glucans, and glucosamine. Exemplary antimicrobial agents include phytobotanicals. Exemplary immune boosting agents include zinc and selenium. Exemplary inert carriers include water or other inert carriers known in the art.
- The amounts of each of the components in the final product may be varied depending upon the nature of the additional components, the weight and condition of the animal to be treated, and the unit dosage desired. Those of ordinary skill in the art will be able to adjust dosage amounts as required.
- Exemplary forms of the compositions of the invention include soft chews, powders, capsules, tablets, boluses, pastes, liquids, foods, animal feeds, candies, drinks, pastes, liquids, and creams. Exemplary composition forms suitable for oral administration include tablets, boluses, pastes, capsules, liquids, such as human foods, animal feeds, candy, soft chews, or drinks. Exemplary composition forms suitable for topical administration include pastes, liquids, gels, or creams.
- The components of the invention can be placed into capsules, boluses, and tablets for oral administration or in pastes, liquids, gels, or creams for topical administration in times of oxidative stress from diseases or to maintain optimum immunity health on a daily basis. The components of the invention may also be placed into human foods and animal feeds including cereals, soups, liquid drinks, candy, pharmaceuticals aids including band aids, skin care beauty creams, and pastes.
- Some versions of the invention include the tetrahydrocurcuminoid-metal complex in combination with any one or more, in any combination, of black elderberry (a phytonutrient supporting immune function and promoting a healthy respiratory system), selenium (a micronutrient that helps fight cellular damage), vitamin D3 (builds immunity in times of stress), vitamin C (ascorbic acid, an antioxidant for maintaining production of white blood cells), phycocyanin (a Spirulina extract that provides support by helping to maintain normal interferon levels during oxidative stress), ferulic acid (an organic compound with antioxidant properties that support the body during stress), and piperine (black pepper extract that helps the body by increasing bioavailability of nutraceuticals like curcumin). These components can be included in powder form. The components can be encapsulated in a capsule or provided in any other form provided herein.
- The compositions can be used in methods of reducing stress, reducing oxidative stress, maintaining health, improving health, improving immunity, improving vaccination efficacy, increasing feed conversion rate, or decreasing pro-inflammatory cytokine levels in an animal in an animal (such as a mammal, human, poultry, etc.). The methods can comprise administering a composition of the invention to the animal in a therapeutically effective amount. The therapeutically effective amount can include an amount effective to reduce stress, reduce oxidative stress, maintain health, improve health, improve immunity, improve vaccination efficacy, increase feed conversion rate, or decrease pro-inflammatory cytokine levels in an animal.
- The animal in some versions can include an animal suffering from any condition or disease described herein. Exemplary diseases include cancer, arthritis, inflammatory conditions, cardiovascular conditions, neurological conditions, pulmonary conditions, diabetes, hepatic conditions, gastrointestinal conditions, and an infectious disease, and other conditions that place stresses on the body. Exemplary cardiovascular conditions comprise coronary artery disease, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, and cardiomyopathy, among others. Exemplary neurological conditions comprise diseases of the central and peripheral nervous system, including the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscles. These conditions include epilepsy, Alzheimer disease and other dementias, cerebrovascular diseases including stroke, migraine and other headache disorders, multiple sclerosis, Parkinson's disease, neuroinfections, brain tumors, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition. Exemplary pulmonary conditions include asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, lung cancer, cystic fibrosis/bronchiectasis, pneumonia, pleural effusion, and COVID-19. Exemplary forms of diabetes include
type 1 diabetes andtype 2 diabetes. Exemplary hepatic conditions comprise hepatitis A infection, hepatitis B infection, and hepatitis C infection, fatty liver disease, cirrhosis, liver cancer, and inherited diseases such as hemochromatosis and Wilson disease. Exemplary gastrointestinal conditions comprise celiac disease, irritable bowel syndrome, and irritable bowel disease (Crohn's disease, ulcerative colitis). Exemplary infectious diseases include viral diseases, prion diseases, and bacterial diseases. The animal can include an animal to be or having been vaccinated within a period of 8 weeks, 7 weeks, 6 weeks, 5 weeks, 4 weeks, 3 weeks, 2 weeks, 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day. The therapeutically effective amount can be an amount effective to ameliorate the condition or disease or a symptom of the condition or disease. - The animal can comprise any animal. The animal can comprise a human or a non-human animal. The animal can comprise a mammal. Exemplary mammals include humans, bovines, swine, sheep, goats, dogs, cats, primates, apes, monkeys, and rodents. The animal can comprise a bird, such as poultry. The animal can comprise other types of animal, such as fish or reptiles. In some versions, the animal comprises a production animal. Production animals are animals that are farmed for food or products derived therefrom. Exemplary production animals include bovines (including cattle), ovines (including sheep), caprines (including goats), avines (including birds such as poultry), cervines (including deer), porcines (including pigs), reptilians (including reptiles), and piscines (including fish).
- The compositions of the invention can be used as feed additive to help animals (such as production animals) gain weight faster. In some versions, the compositions can serve as an alternative to antibiotics intended for weight gain and growth promotion in production animals. The animal in such versions can comprise any production animal, such as bovines (including cattle), ovines (including sheep), caprines (including goats), avines (including birds such as poultry), cervines (including deer), porcines (including pigs), reptilians (including reptiles), piscines (including fish), or any other production animal. In some versions, the composition is administered in an amount effective to increase feed conversion rate in the animal relative to a control animal not receiving the composition.
- In some versions, the composition is administered in an amount effective to decrease serum levels of a pro-inflammatory cytokine in the animal relative to a control animal not receiving the composition. Exemplary pro-inflammatory cytokines include IL-2, IL-8, IL-6, IL-7, IL-15, IL-18, MCP-1, TNFα, and IL-1-beta.
- Some versions of the invention comprise a mixture comprising free tetrahydrocurcuminoid (uncomplexed tetrahydrocurcuminoid) and free zinc (uncomplexed zinc) in the form of a dry powder. The free tetrahydrocurcuminoid can comprise tetrahydrocurcumin. The mixture can be made without the use of a solvent. The mixture can be administered to an animal directly in powder form or mixed with a carrier before administering. The mixture can also or alternatively be solubilized in a solvent as described herein to permit complexation of the tetrahydrocurcuminoid and the zinc. The tetrahydrocurcuminoid and the zinc can be present in the mixture in a ratio from 0.001:1 (tetrahydrocurcuminoid:zinc) to 1000:1 (tetrahydrocurcuminoid:zinc), such as a ratio from 0.01:1 (tetrahydrocurcuminoid:zinc) to 100:1 (tetrahydrocurcuminoid:zinc).
- Some versions of the invention comprise a mixture comprising free tetrahydrocurcuminoid (uncomplexed tetrahydrocurcuminoid), free curcuminoid (uncomplexed curcuminoid), and free zinc (uncomplexed zinc) in the form of a dry powder. The free tetrahydrocurcuminoid can comprise tetrahydrocurcumin. The free curcuminoid can comprise curcumin. The mixture can be made without the use of a solvent. The mixture can be administered to an animal directly in powder form or mixed with a carrier before administering. The mixture can also or alternatively be solubilized in a solvent as described herein to permit complexation of the tetrahydrocurcuminoid, the curcuminoid, and the zinc. The tetrahydrocurcuminoid and the zinc can be present in the mixture in a ratio from 0.001:1 (tetrahydrocurcuminoid:zinc) to 1000:1 (tetrahydrocurcuminoid:zinc), such as a ratio from 0.01:1 (tetrahydrocurcuminoid:zinc) to 100:1 (tetrahydrocurcuminoid:zinc); the zinc and curcuminoid can be present in a ratio from 0.001:1 (zinc:curcuminoid) to 1000:1 (zinc:curcuminoid), such as a ratio from 0.01:1 (zinc:curcuminoid) to 100:1 (zinc:curcuminoid); and/or the tetrahydrocurcuminoid and curcuminoid can be present in a ratio from 0.001:1 (tetrahydrocurcuminoid:curcuminoid) to 1000:1 (tetrahydrocurcuminoid:curcuminoid), such as a ratio from 0.01:1 (tetrahydrocurcuminoid:curcuminoid) to 100:1 (tetrahydrocurcuminoid:curcuminoid).
- The elements and method steps described herein can be used in any combination whether explicitly described or not.
- All combinations of method steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.
- As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise.
- Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
- All patents, patent publications, and peer-reviewed publications (i.e., “references”) cited herein are expressly incorporated by reference to the same extent as if each individual reference were specifically and individually indicated as being incorporated by reference. In case of conflict between the present disclosure and the incorporated references, the present disclosure controls.
- It is understood that the invention is not confined to the particular construction and arrangement of parts herein illustrated and described, but embraces such modified forms thereof as come within the scope of the claims.
- One mole of tetrahydrocurcumin was solvated in anhydrous ethanol and placed into a beaker. One mole of zinc chloride was solvated in anhydrous ethanol and placed into the same beaker. A stir bar was added, and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-tetrahydrocurcumin complex. The mixture was placed into a rotoevaporator flask, and the ethanol was removed. The tetrahydrocurcumin-zinc-tetrahydrocurcumin complex was placed into a Buchner funnel and thoroughly washed with water to remove unreacted components. The washed complex was dried at 50° C. until a dry powder was formed. The complex was analyzed for zinc content to quantify the amount of zinc in the complex. It was found that 23% of the starting zinc remained in the dried tetrahydrocurcumin powder, consistent with zinc being bound by chelation bonds to tetrahydrocurcumin.
- Two moles of tetrahydrocurcumin were solvated in anhydrous ethanol and placed into a beaker. One mole of zinc chloride was solvated in anhydrous ethanol and placed into the same beaker. A stir bar was added, and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-tetrahydrocurcumin complex. The mixture was placed into a rotoevaporator flask, and the ethanol was removed. The tetrahydrocurcumin-zinc-tetrahydrocurcumin complex was placed into a Buchner funnel and washed with water to remove unreacted components. The washed complex was dried at 50° C. until a dry powder was formed. The complex was analyzed for zinc content to quantify the amount of zinc in the complex.
- One mole of tetrahydrocurcumin was solvated in propylene glycol and placed into a beaker. One mole of zinc chloride was solvated in water and placed into the same beaker. The propylene glycol:water ratio was 1:1. A stir bar was added and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-tetrahydrocurcumin complex. The tetrahydrocurcumin-zinc-tetrahydrocurcumin complex was placed into a Buchner funnel and washed with water to remove unreacted components. The washed complex was dried at 50° C. until a dry powder was formed. The complex was analyzed for zinc content to quantify the amount of zinc in the complex.
- 0.25 moles of tetrahydrocurcumin and 0.75 moles of curcumin were solvated in methanol to create 1 mole of ligand and placed in a beaker. One mole of zinc acetate anhydrous was solvated in methanol and added to the beaker to give a 1:1 molar ratio of ligand:metal. A stir bar was added, and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-curcumin complex. The mixture was placed into a rotary evaporator flask, and the methanol was removed. The tetrahydrocurcumin-zinc-curcumin complex was placed into a Buchner funnel and washed with water to remove unreacted components. The washed complex was dried at 50° C. until a dry powder was formed. The complex was analyzed for zinc content to quantify the amount of zinc in the complex. UV and FTIR analysis showed characteristic changes in profiles compared to the control material of methanol-solvated tetrahydrocurcumin and curcumin mixture.
- One mole of tetrahydrocurcumin and 1 mole of curcumin were solvated in methanol to create 2 moles of ligand and placed in a beaker. One mole of zinc acetate anhydrous was solvated in methanol and added to the beaker to give a 2:1 molar ratio of ligand:metal. A stir bar was added, and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-curcumin complex. The mixture was placed into a rotary evaporator flask, and the methanol was removed. The complex of tetrahydrocurcumin-zinc-curcumin was placed into a Buchner funnel and washed with water to remove unreacted components. The washed complex was dried at 50° C. until a dry powder was formed. The complex was analyzed for zinc content to quantify the amount of zinc in the complex. UV and FTIR analysis showed characteristic changes in profiles compared to the control material of methanol-solvated tetrahydrocurcumin and curcumin mixture.
- One mole of tetrahydrocurcumin and 1 mole of curcumin were solvated in methanol to create 2 moles of ligand and placed in a beaker. One mole of zinc chloride was solvated in methanol and added to the beaker to give a 2:1 molar ratio of ligand:metal. A stir bar was added, and the mixture was stirred for 2 hours at room temperature to create a tetrahydrocurcumin-zinc-curcumin complex. It was noted that the component mixture turned from an initial yellow color at time zero into a red color by 2 hours as it became a complex. A change from yellow color to a red color is consistent with molecular changes to curcumin as zinc binds to it due to structural chromophore changes. The complex was placed into a rotoevaporator flask, and the methanol was removed to result in a red color powder matrix complex.
- An aliquot of the complex was dissolved in 100% acetic acid and purified on a Sephadex G25 column with acetic acid as the running buffer. It was noted that a red color band migrated through the column while a yellow color remained bound throughout the entire column after the purification run was completed. These color banding results are consistent with the red band being a zinc complexed to curcumin and tetrahydrocurcumin while the yellow band is consistent with unreacted free curcumin and unreacted free tetrahydrocurcumin. The red color is consistent with a molecular structure change when zinc binds to diketols located in the center part curcumin and tetrahydrocurcumin molecules.
- 1 mole (372.4 grams) of tetrahydrocurcumin was added to 1 mole (136 grams) of ZnCl2 and 1 liter of methanol was added to solvate the materials into a clear solution. This clear solution mixture was at pH 2.0. The mixture was dried into a powder by rotoevaporation, analyzed for changes in the UV profile and FTIR profile, and compared to the control tetrahydrocurcumin starting material that was not subjected to complexation with zinc.
FIGS. 5A and B show a shift of the peak at 283 nm in the UV profile for the control material (FIG. 5A ) to 286 nm for the pH 2.0 complex (FIG. 5B ). FTIR profiles of the pH 2.0 tetrahydrocurcumin-zinc complex also revealed changes at 3397, 970, and 450 wavenumbers (FIGS. 6A and 6B ). These changes are consistent with zinc binding to tetrahydrocurcumin and changing the structural conformation when complexation occurs. It is concluded that both the UV and the FTIR profile are consistent with zinc binding to tetrahydrocurcumin and causing a complexation reaction and the formation of a new molecule. - 1 mole (372.4 grams) of tetrahydrocurcumin was added to 1 mole (136 grams) of ZnCl2, and 1 liter of methanol was added to solvate the materials into a clear solution. This clear solution mixture was at pH 2.0. Half of this mixture was placed in a separate beaker and the pH was raised to pH 7.5 using triethylamine. It was unexpectedly noted that an immediate white precipitate occurred in the mixture when the pH was raised. Both mixtures were stirred at room temperature for 24 hours. The mixtures were dried into a powder by rotoevaporation, analyzed for changes in the UV profile and FTIR profile, and compared to the control tetrahydrocurcumin starting material that was not subjected to complexation with zinc.
FIGS. 5A and 5B show a shift of the peak at 283 nm in the UV profile for the control material (FIG. 5A ) to 286 nm for the pH 2.0 complex (FIG. 5B ). This shift further increased to 292 nm with the pH 7.5 tetrahydrocurcumin-Zn complex material, and a broadening of the lagging side peak occurred (FIG. 5C ). FTIR profiles of the pH 2.0 tetrahydrocurcumin-Zn complex revealed changes at 3397, 970, and 450 wavenumbers (FIGS. 6A and 6B ). These changes are consistent with zinc binding to tetrahydrocurcumin and changing the structural conformation when complexation occurs. FTIR profiles of the pH 7.5 tetrahydrocurcumin-Zn complex revealed changes at 1576, 1426, and 2980 wavenumbers as compared to the starting tetrahydrocurcumin material (FIGS.FIGS. 6A and 6C ). These changes are consistent with binding of zinc to hydroxyl groups in the central part of the structure and thus changing the structure of tetrahydrocurcumin. It is concluded that both the UV and the FTIR profiles are consistent with zinc binding to tetrahydrocurcumin and causing a complexation reaction and the formation of a new molecule. When the reaction is carried out at pH 7.5, the reaction is presumably enhanced due to changes predominately of keto into enol forms of tetrahydrocurcumin. This unexpected finding is a novel manner to improve chelation of zinc to tetrahydrocurcumin. It is concluded that zinc can complex to tetrahydrocurcumin at either pH 2.0 or pH 7.5 and change UV and FTIR profiles vs control tetrahydrocurcumin without zinc present. The data are consistent with the complexation being more efficient at pH 7.5. - As tetrahydrocurcumin has some different biological properties than curcumin, having different ratios of tetrahydrocurcumin to curcumin in the zinc complex of the invention can extend the efficacy of the invention for different disease and health conditions. As such, the ratio of tetrahydrocurcumin to curcumin during complexation to zinc was examined. In addition, the pH during the complexation reaction was examined at acidic and at neutral pH. Ratios of 25:75, 50:50, and 75:25 of tetrahyrdocurcumin:curcumin were created by weighing out relative amounts tetrahydrocurcumin and curcumin based on molecular weights of each and mixing together to form a uniform powder. A 2-mole amount of the uniform mixed ratios of tetrahydrocurcumin:curcumin were added to a 1-mole amount of zinc chloride. One liter of methanol was added to solvate the mixture, and the pH was noted to be pH 4.0. Half of the solvated solution was removed to a different beaker, and the pH was raised to pH 7.0 using triethylamine. Raising the pH from
pH 4 topH 7 changed the color from a yellow/orange to red. All 6 sets of the mixed ratio solutions were stirred at room temperature for 24 hours. The solutions were dried to a powder by rotoevaporation and subjected to UV and FTIR analysis. The 250 mg of dried powders were dissolved in 1 ml acetone and were subsequently purified using Sephadex G-10 low pressure chromatography with a 45:55 acetone:water solvent to separate the complexed powders based on molecular weight. Absorbance atOD 425 and pH were monitored for the eluted fractions (FIGS. 7A-7F ). Different color bands migrated through the column that corresponded to different molecular weights. The leading edge of the pH 7.0 complexes were dark red while lagging subsequent fractions were yellow/orange. The pH of fractions decreased with a corresponding increase ofOD 425 that recovered as less OD was eluting (FIGS. 7A-7F ). These data are consistent with leading edge the profile having larger molecular weight that was complexed with zinc. The lagging edge fractions are consistent with containing unbound curcumin and unbound tetrahydrocurcumin. The data indicate that various ratios of curcumin:tetrahydrocurcumin can be complexed with zinc in the invention. - During the purification of the 25:75 curcumin:tetrahydrocurcumin ratio complex with zinc at pH 7.0, the leading edge fractions when dried contained both red crystals and yellow/white crystals. These crystals are consistent with the formation of novel tetrahydrocurumin-zinc-curcumin complexes of the invention. These crystals were subjected to UV (
FIGS. 8A and 8B ) and FTIR analysis (FIGS. 9A and 9B ). - The UV and FTIR of purified fractions are consistent with the formation of a novel molecular complex of tetrahydrocurcumin and curcumin concurrently bound to zinc. Different ratios of curcumin to tetrahydrocurcumin can be utilized when binding to zinc. Raising the pH of the reaction from acidic conditions to neutral conditions allows for the change of the predominant keto forms of the reactants to an enol form. This change unexpectedly allows for more efficient binding of the diavalent zinc concurrently to both curcumin and tetrahydrocurcumin with subsequent greater changes observed in UV and FTIR profiles.
- Cellular transport studies of the invention were performed in 6-well transwell plates using triplicate wells for each timepoint to show that the complexes of the invention cross cell membranes to become bioavailable. Pig intestinal IPEC J2 cells were used and grown to confluence using DME medium and 5% fetal calf serum. The cells were washed with saline. One milliliter of saline was present in the bottom wells at all times. Curcumin, tetrahydrocurcumin, and a 75:25 mixture of curcumin:tetrahydrocurcumin were complexed with ZnCl2 as described in Examples 7 and 9. 2.0 mg of curcumin, curcumin-Zn complex, tetrahydrocurcumin, tetrahydrocurcumin-Zn complex, and tetrahydrocurcumin-Zn-curcumin complex were solubilized in saline with 5.0% DMSO, and 1 ml was placed in the top wells and incubated for 2 hours at 37°
C. OD 425 nm and OD 220 nm were measured in the top and bottom wells spectrophotometrically or by HPLC.OD 425 nm is representative of curcumin, curcumin-Zn complexes, and tetrahydrocurcumin-Zn-curcumin complexes. OD 220 nm is representative of tetrahydrocurcumin and tetrahydrocurcumin-Zn complexes. The % net uptake of the respective agents were calculated by summing the OD in the upper and lower wells and then dividing the sum by the bottom well OD and graphed as shown inFIG. 10A . The data indicate that zinc improved the uptake of tetrahydrocurcumin by >2 fold. A similar amount of uptake was observed in the tetrahydrocurcumin-Zn-curcumin complex as compared to the tetrahydrocurcumin-Zn complex. The data indicate in this particular cell culture system that some curcumin crossed membranes, with or without the presence of zinc. However, when the curcumin was complexed to zinc in the presence of tetrahydrocurcumin, an unexpected 5-fold increase occurred as seen inFIG. 10B . This is consistent with the efficacy of the complexes of the invention to improve bioavailability of curcumin presumably by the presence of tetrahydrocurcumin being complexed to the curcumin to allow better uptake. - An animal trial was conducted to determine the bioavailability of the complexes of the invention in blood. One gram of curcumin was suspended in 5 ml of water and placed into a syringe. One gram of tetrahydrocurcumin was suspended in 5 ml of water and placed into another syringe. One gram of a tetrahydrocurcumin-Zn-curcumin complex of the invention as created in Example 9 was suspended in 5 ml of water and placed into another syringe. Three chickens (Rhode Island Red) that were each 2 years old weighing 5 pounds were selected, and 1 ml of blood was removed from the wing vein for baseline measurements. The blood was allowed to clot and the plasma was removed by centrifugation for subsequent baseline analysis. The chickens were allowed to rest overnight. The contents of each of the respective syringes were then administered to separate chickens via the mouth, ensuring that the contents were consumed. Blood was removed at 2, 4, and 24 hours from each bird and allowed to clot. The recovered serum was mixed with equal volumes of acetone via vortexing for 30 seconds and then centrifuged to remove proteins in the pellet while recovering curcumin, tetrahydrocurcumin, or the elements of the tetrahydrocurcumin-Zn-curcumin complex in the supernatant. The supernatants from each time point were analyzed by standard HPLC methods for the presence of curcumin, tetrahydrocurcumin, or the tetrahydrocurcumin-Zn-curcumin complex at 280 nm and 425 nm wavelengths. The results show that peaks due to curcumin, tetrahydrocurcumin, or the tetrahydrocurcumin-Zn-curcumin complex could be seen at the 2-hour, 4-hour, and 24-hour timepoints in each of the respective samples. However, the tetrahydrocurcumin-Zn-curcumin complex had 2 to 3 times as much peak area at the 1.996 min chromatogram retention peak as curcumin or tetrahydrocurcumin for the 2-hour timepoint (
FIG. 11 ). This result is consistent with an increased bioavailability of the tetrahydrocurcumin-Zn-curcumin of the invention in an animal by 2 hours as compared to just curcumin or tetrahydrocurcumin. Furthermore, the data show that the tetrahydrocurcumin-Zn-curcumin complex is metabolized over time as evidenced by the disappearance of HPLC peaks and the appearance of new HPLC peaks in the serum at 24 hours, as seen in chromatograms analyzed at 280 nm (FIGS. 12A-12C ) and 425 nm (FIGS. 13A-13C ). This unexpected result is consistent with an increased bioavailability and increased longevity of the tetrahydrocurcumin-Zn-curcumin complex of the invention in blood not seen with curcumin alone or tetrahydrocurcumin alone. The data also show acute safety of the invention at 1 g/lb. body weight, as the 5-lb birds did not die nor show any ill effects when orally ingesting 1 gram of the invention. - A live animal trial was conducted to determine the effects of a tetrahydrocurcumin-Zn-curcumin complex to improve health. Increased weight gain in newborn chickens receiving the tetrahydrocurcumin-Zn-curcumin complex as compared to control newborn chickens that did not receive the tetrahydrocurcumin-Zn-curcumin complex in the same time frame is a measure of improved health and efficacy of the invention. The trial was conducted over a 6-week period. Three groups of N=11/group day-old chickens (Cornish cross males) were placed in three identical pens with identical size (5 foot×5 foot), lighting, heat, water, and feeder apparatus. One chicken group served as control, one group received 0.5% w/w of the tetrahydrocurcumin-Zn-curcumin complex mixed into the feed, and another group received 1.0% w/w of the tetrahydrocurcumin-Zn-curcumin complex mixed into the feed. The tetrahydrocurcumin-Zn-curcumin complex used in the trial was the powder created by mixing 75% curcumin with 25% tetrahydrocurcumin and complexed with zinc chloride in a 2:1 molar ratio as described in Example 9. The feed used throughout the trial was standard poultry feed mash to ensure uniform mixing of the invention. Chickens were weighed on weekly basis and the amount of feed consumed was recorded. Results are shown in
FIG. 14A . The results indicated that chickens that received 0.5% of the tetrahydrocurcumin-Zn-curcumin complex in their feed statistically weighed more than the control birds byweek 3 and at the end of trial (p<0.05). Birds that received 1% of the tetrahydrocurcumin-Zn-curcumin complex also weight more than control birds at week 3 (p<0.05) although unexpectantly not as much as birds that received 0.5%. - The feed conversion ratio (FCR) was calculated on a weekly basis for the different groups for the amount of feed consumed relative to the amount of weight gain. The averages of the weekly FCRs for the entire trial from
week 0 toweek 6 are reported in graphFIG. 14B . The data indicate that birds receiving 0.5% of the tetrahydrocurcumin-Zn-curcumin complex in feed had a lower and thus better FCR than the control group over the course of the trial. The group receiving 1.0% of the tetrahydrocurcumin-Zn-curcumin complex had a lower and even better FCR than the 0.5% group. - The results of the feed trial with the use of the tetrahydrocurcumin-Zn-curcumin complex indicate the efficacy of the invention for improving weight gain in chicken in a statistically significant manner. As weight-gain in chickens is related to overall health, these data are consistent with the complexes of the invention to improve overall health in animals. The data are consistent with the complexes of the invention reducing oxidative stress and modifying the gut microbiome in a favorable manner that allows for improved FCR in chickens or other animals. The data also show favorable chronic use safety of the invention, as no birds died or showed any ill effects as result of ingesting the composition on a daily basis for 6 weeks fed at approximately 5 g/lb. body weight. This is about 100× the fed level seen in humans for curcumin of 0.05 g/lb. body weight for safe chronic ingestion, thus indicating safety of chronic consumption of the invention.
- Levels of certain cytokines in serum have been used as a measure of general health in animals. A live animal trial was conducted to determine the effects of a tetrahydrocurcumin-zinc-curcumin complex on cytokine levels in serum. The cytokines of interleukin 1-beta (IL-1-beta), interleukin 6 (IL-6), interleukin 10 (IL-10), and interferon gamma were measured at the end of a 6-week period in newborn chickens receiving the tetrahydrocurcumin-zinc-curcumin complex on a daily basis as compared to control newborn chickens that did not receive the tetrahydrocurcumin-zinc-curcumin complex in the same time frame. The trial was conducted over a 6-week period and was part of the weight gain trial described above in Example 12. Three groups of N=3/group day-old chickens (Cornish cross males) were placed in three identical pens with identical size (5 foot×5 foot), lighting, heat, water, and feeder apparatus. One chicken group served as a control, one group received 0.5% w/w of the tetrahydrocurcumin-zinc-curcumin complex mixed into the feed, and another group received 1.0% of the tetrahydrocurcumin-zinc-curcumin complex mixed into the feed. The tetrahydrocurcumin-zinc-curcumin complex used in the trial was a powder created by mixing 75% curcumin with 25% tetrahydrocurcumin and complexed with zinc chloride in a 2:1 molar ratio as described in Example 9. The feed used throughout the trial was standard poultry feed mash to ensure uniform mixing of the invention.
- At the end of the 6 week period, blood samples were taken and allowed to clot into serum. The serum was tested by commercial ELISA kits (Cusbio) specific for chicken IL1-beta, chicken IL-6, chicken IL-10, and chicken interferon gamma using the directions from the manufacture. As shown in
FIGS. 15A-15D , administration of the tetrahydrocurcumin-zinc-curcumin complex reduced the amount of IL-1-beta (FIG. 15A ) and IL-6 (FIG. 15B ) circulating in the blood of the chickens but did not affect the amounts of IL-10 (FIG. 15C ) or interferon gamma (FIG. 15D ). - These results are consistent with administration of the tetrahydrocurcumin-zinc-curcumin complex being able to block the production of the pro-inflammatory cytokines IL-1 beta and IL-6. This reduction is also consistent with the increased growth and weight gain observed in these chickens compared to control birds as described in Example 12. Having lower amounts pro-inflammatory cytokines present allows for healthier growth and increased weight gain since the animal can expend its energy in productive ways for weight gain.
- The lack of a change with interferon gamma and IL-10 levels is consistent with the birds in the trial lacking active viral infections at the beginning and throughout the trial. Interferon gamma and IL-10 levels tend to be elevated if viral diseases are present. Because no obvious viral diseases were present in these birds at the beginning and throughout the trial, it is not surprising that administration of tetrahydrocurcumin-zinc-curcumin complex did not alter the levels of these cytokines.
- The antioxidant activity of a tetrahydrocurcumin-Zn-curcumin complex of the invention was measured and compared to curcumin and tetrahydrocurcumin. A standard DPPH (2,2-diphenyl-1-picryl-hydrazyl-hydrate) antioxidant assay was used to predict antioxidant activities, for example, by mechanisms in which antioxidants act to inhibit lipid oxidation. The assay scavenges the DPPH radical and therefore determines free radical scavenging capacity of test subjects. The test subjects were administered the tetrahydrocurcumin-Zn-curcumin, curcumin, or tetrahydrocurcumin. The tetrahydrocurcumin-Zn-curcumin was made as in Example 9 with a 25:75 ratio of tetrahydrocurcumin:curcumin at pH 4.0. The curcumin controls and tetrahydrocurcumin controls were from the same starting material used to make the tetrahydrocurcumin-Zn-curcumin.
- The DPPH free radical method is an antioxidant assay based on electron-transfer that produces a violet solution in ethanol. DPPH is a free radical that is stable at room temperature and is reduced in the presence of an antioxidant molecule to give rise to a yellow colored product, diphenylpicryl hydrazine, in ethanol solution. DPPH free radical scavenging is an accepted mechanism for screening the antioxidant activity. The method is widely used due to relatively short time required for the analysis. The free radical scavenging ability of the curcumin, tetrahydrocurcumin, and tetrahydrocurcumin-Zn-curcumin was tested by DPPH radical scavenging assay as per the manufacturer's instruction (Dojindo Molecular Technologies, Inc., Kumamoto, Japan).
- Briefly, a solution of 10 mL DPPH in ethanol was prepared, and 100 μl of this solution was mixed with 20 μl of the curcumin, tetrahydrocurcumin, or tetrahydrocurcumin-Zn-curcumin in ethanol at different concentrations (0.125-0.50 mg/mL). The reaction mixture was mixed thoroughly and left in the dark at RT for 30 min. The absorbance of the mixture was measured spectrophotometrically at 517 nm. Trolox was used as reference. Percentage DPPH radical scavenging activity was calculated by the following equation:
-
DPPH radical scavenging activity (%)=(Acs−As)/Acs×100 - Acs:
Blank 1−Blank 2 - As: Absorbance of samples−
Blank 2 - Then % of inhibition was plotted against concentration.
- All compounds (curcumin, tetrahydrocurcumin, and tetrahydrocurcumin-Zn-curcumin) exhibited antioxidant activity by scavenging free radicals (
FIG. 16 ) in a dose-dependent manner. Curcumin alone had lowest antioxidant activity among them. Tetrahydrocurcumin exerted a higher antioxidant activity than curcumin but less than the tetrahydrocurcumin-Zn-curcumin. The tetrahydrocurcumin-Zn-curcumin showed the highest level of antioxidant activity as compared to the curcumin or tetrahydrocurcumin. An unexpectant synergistic antioxidant activity of the invention occurred as the amount of antioxidant activity of the tetrahydrocurcumin-Zn-curcumin is much greater than a simple additive effect of the starting curcumin with the starting tetrahydrocurcumin. This unexpected synergistic action can be observed at all doses, but especially with the smallest dose (0.125 mg/ml) in the assay. These results indicate the excellent efficacy of the tetrahydrocurcumin-Zn-curcumin of the invention for vastly improved antioxidant activity over the starting materials of curcumin or tetrahydrocurcumin alone, and at relatively low concentrations. - A tetrahydrocurcumin-Zn-curcumin complex of the invention was examined for its ability to influence cytokine release in a cell culture system. Cytokine release leads to systemic inflammatory syndromes involving elevated levels of circulating cytokines and immune-cell hyperactivation. The cytokine release can be triggered by various stresses, viral pathogens like Covid-19, cancers, autoimmune conditions, and monogenic disorders. In cell culture systems, lipopolysaccharide (LPS) is commonly used as stressor to induce cytokine release.
- MDCK cells were cultured in a DMEM media supplemented with FBS and antibiotic and were maintained in a humidified atmosphere of 5% CO2 and 95% humidity. Almost 70% confluent cells were treated with different concentrations of tetrahydrocurcumin-Zn-curcumin, curcumin, or tetrahydrocurcumin (0.125, 0.25, 0.5, or 1 mg/ml) in plates containing 3 mL of DMEM. The tetrahydrocurcumin-Zn-curcumin was made as described in Example 9. The curcumin controls and tetrahydrocurcumin controls were from the same starting material used to make the tetrahydrocurcumin-Zn-curcumin. After 2 hours, cells were treated with LPS (8 μg/ml) and incubated for 24 hours. Media were harvested and cytokines were measured using Canine Cytokine Array/Chemokine Array 13-Plex (CD13) at a commercial laboratory (Eve Technologies, Calgary, Calif.).
-
FIGS. 17A-17I show lipopolysaccharide (LPS)-stimulated cytokine release in the absence or presence of tetrahydrocurcumin-Zn-curcumin (data were analyzed using GraphPad Prism). LPS stimulated cytokine release over the baseline levels in all cases, except for GM-CSF where the baseline level was zero to begin with. Tetrahydrocurcumin-Zn-curcumin consistently reduced the LPS-stimulated cytokine levels to below baseline levels in a dose-dependent manner. However, in the case of GM-CSF, tetrahydrocurcumin-Zn-curcumin stimulated the release of this particular cytokine. - Cytokines are a diverse group of small proteins that are secreted by cells for the purpose of intercellular signaling, and many, but not all, are associated with pro-inflammatory reactions in the body. Reducing cytokine release from stressed cells or enhancing certain cytokines is important for maintaining the overall health of a human or animal.
- IL-2 promotes inflammatory responses and functions to stimulate T-cell growth in asthma, atopic dermatitis, auto immune diseases, cancer and inflammatory bowel disease. The reduction in IL-2 resulting from administration with the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to overall health to an individual with these conditions.
- IL-8 plays a pro-inflammatory role as a chemoattractant recruitment of neutrophils. Babesia parasite infection in dogs causes increased level of IL-8. The reduction in IL-8 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to animals with this parasite infection.
- IL-6 is associated with pro-inflammatory responses and responsible for many inflammatory diseases in both humans and animals. In synovial fluid of dogs with cranial cruciate ligament rupture have high level of IL-6 that may results in arthritic symptoms. IL-6 may be involved in the pathogenesis of tubule-glomeruli injury and subclinical ehrlichiosis may lead in chronic kidney disease in dogs. The reduction of IL-6 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals suffering from arthritis or other diseases.
- IL-7 causes cartilage matrix degradation that may results in joint destruction. High expression of IL-7 causes bone destruction in dogs. IL-7 is overexpressed during viral infection in dogs. The reduction of IL-7 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals suffering from arthritis or other diseases.
- IL-15 is a pro-inflammatory cytokine that is expressed in several inflammatory disorders, including rheumatoid arthritis, psoriasis, and pulmonary inflammatory diseases. IL-15 and IL-18 are elevated in pyometra disease in dogs. Pyometra is caused by bacterial infection of the uterus and can result in systemic inflammatory response syndrome. The reduction of IL-15 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals with these or similar health conditions.
- IL-18 has been implicated in several autoimmune diseases, myocardial function, metabolic syndromes, psoriasis, inflammatory bowel disease, hemophagocytic syndromes, macrophage activation syndrome, sepsis, mental cognition issues, and acute kidney injury. IL-18 is highly expressed in dogs with metaphyseal osteopathy (an inflammatory bone disease). the reduction of IL-18 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals with these health conditions.
- Monocyte chemoattractant protein-1 (MCP-1) is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages to produce inflammation. Babesia infection in dogs causes increased level of MCP-1 and further inflammation. The reduction of MCP-1 resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals with these health conditions.
- TNF-α is responsible for range of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis. TNF-α is noticeably up-regulated in dogs with visceral leishmaniasis disease and chronic kidney disease, and thus considered as a key factor for the initiation, maintenance, and persistence of inflammation. A reduction of TNF-α resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, to both humans and animals with these health conditions
- Granulocyte-macrophage colony stimulating factor (GM-CSF) stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. GM-CSF improves intestinal barrier integrity by augmenting innate immune responses. Acutely increased GM-CSF levels resulting from administration of the tetrahydrocurcumin-Zn-curcumin of the invention would be beneficial, for example, for immunity and improving health in humans and animals.
- Collectively, these examples and results show the efficacy of the tetrahydrocurcumin-Zn-curcumin of the invention for reducing pro-inflammatory cytokines or augmenting levels of beneficial cytokines. The tetrahydrocurcuminoid-metal complexes can be administered to animals to increase animal health, reduce stress, reduce oxidative stress, maintain health, improve health, improve immunity, improve vaccination efficacy, increase feed conversion rate, and/or decrease pro-inflammatory cytokine levels in an animal.
- 0.25 moles of tetrahydrocurcumin and 0.75 moles of curcumin were mixed together to create 1 mole of ligand as a dry powder and placed in a beaker. One mole of zinc chloride was added to the beaker to give a 1:1 molar ratio of ligand:metal and mixed to form a dry powder mixture of tetrahydrocurcumin, curcumin, and zinc chloride.
-
- Aggarwal B. B., Deb L. and Prasad S. Curcumin Differs from Tetrahydrocurcumin for Molecular Targets, Signaling Pathways and Cellular Responses.
Molecules 2015, 20, 185-205. - Dai J, Gu L, Su Y, Wang Q, Zhao Y, Chen X, Deng H, Li W, Wang G, Li K. Inhibition of curcumin on influenza A virus infection and influenzal pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-κB pathways. Int Immunopharmacol. 2018 January; 54:177-187. doi: 10.1016/j.intimp.2017.11.009. Epub 2017 Nov. 15.
- Fosmire G J. Zinc toxicity. Am J Clin Nutr. 1990 February; 51(2):225-7.
- Hieu T. Q. and Thao D. T. T. Enhancing the Solubility of Curcumin Metal Complexes and Investigating Some of Their Biological Activities. Journal of Chemistry Volume 2019,
Article ID 8082195, 8 pages https://doi.org/10.1155/2019/8082195 - Ostrowski W., Uniecikowska L., Hoffmann M., and Franski R. Demethoxycurcumin-Metal Complexes: Fragmentation and Comparison with Curcumin-Metal Complexes, as Studied by ESI-MS/MS Journal of Spectroscopy. Volume 2013,
Article ID 749641, 8 pages http://dx.doi.org/10.1155/2013/749641 - McCarty, Mark F, and James J DiNicolantonio. “Nutraceuticals have potential for boosting the
type 1 interferon response to RNA viruses including influenza and coronavirus.” Progress in cardiovascular diseases, S0033-0620(20)30037-2. 12 Feb. 2020, doi:10.1016/j.pcad.2020.02.007 - Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998 May; 64(4):353-6.
Claims (30)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/319,496 US20210353583A1 (en) | 2020-05-14 | 2021-05-13 | Tetrahydrocurcuminoid-metal complexes, manufacturing methods thereof, and uses thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063024904P | 2020-05-14 | 2020-05-14 | |
US202063119719P | 2020-12-01 | 2020-12-01 | |
US17/319,496 US20210353583A1 (en) | 2020-05-14 | 2021-05-13 | Tetrahydrocurcuminoid-metal complexes, manufacturing methods thereof, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210353583A1 true US20210353583A1 (en) | 2021-11-18 |
Family
ID=76444541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/319,496 Pending US20210353583A1 (en) | 2020-05-14 | 2021-05-13 | Tetrahydrocurcuminoid-metal complexes, manufacturing methods thereof, and uses thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210353583A1 (en) |
EP (1) | EP4149487A1 (en) |
CA (1) | CA3159777A1 (en) |
MX (1) | MX2022009974A (en) |
WO (1) | WO2021231721A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114642241A (en) * | 2022-04-01 | 2022-06-21 | 武汉轻工大学 | Composite plant polyphenol chelate and using method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210230090A1 (en) * | 2018-06-15 | 2021-07-29 | Liliana Patricia Ramirez Rios | Metal complexes of b-diketones and/or polyphenols by green chemistry, preparation method thereof, sunscreen thereof, skin or hair tone concealer thereof, hair dyeing thereof and other uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019008002A1 (en) * | 2017-07-03 | 2019-01-10 | Basf Se | Phenolic metal salts and their phenolic acids as polymer stabilizers |
-
2021
- 2021-05-13 EP EP21732623.0A patent/EP4149487A1/en active Pending
- 2021-05-13 CA CA3159777A patent/CA3159777A1/en active Pending
- 2021-05-13 MX MX2022009974A patent/MX2022009974A/en unknown
- 2021-05-13 WO PCT/US2021/032242 patent/WO2021231721A1/en unknown
- 2021-05-13 US US17/319,496 patent/US20210353583A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210230090A1 (en) * | 2018-06-15 | 2021-07-29 | Liliana Patricia Ramirez Rios | Metal complexes of b-diketones and/or polyphenols by green chemistry, preparation method thereof, sunscreen thereof, skin or hair tone concealer thereof, hair dyeing thereof and other uses thereof |
Non-Patent Citations (3)
Title |
---|
Casi "Tetrahydrocurcumin:The ultimate metabolite of curcuminoids". December 17, 2015. * |
Dr. Colombo et al. "A Highly Luminescent Tetrahydrocurcumin IrIII Complex with Remarkable Photoactivated Anticancer Activity" 2019. * |
Sangartit et al. "Tetrahydrocurcumin Protects against Cadmium induced Hypertension, Raised Arterial Stiffness and Vascular Remodeling in Mice" December 11, 2014. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114642241A (en) * | 2022-04-01 | 2022-06-21 | 武汉轻工大学 | Composite plant polyphenol chelate and using method thereof |
Also Published As
Publication number | Publication date |
---|---|
EP4149487A1 (en) | 2023-03-22 |
CA3159777A1 (en) | 2021-11-18 |
MX2022009974A (en) | 2022-09-12 |
WO2021231721A1 (en) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11426438B2 (en) | Method for treating arthritis with Boswellia serrata extracts | |
AU2023219852A1 (en) | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans | |
EP1254209B1 (en) | Composition comprising hydroxycitric acid and garcinol for weight-loss | |
US20200129463A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
US8828955B2 (en) | Glutathione production enhancer, prophylactic/therapeutic agent for diseases caused by glutathione deficiency, and food, beverage and feed | |
US20030104090A1 (en) | Supplements containing annatto extracts and carotenoids and methods for using the same | |
JP4839436B2 (en) | Gastrointestinal mucosa protective agent, caveolin gene expression promoter and anti-stress agent | |
US20210353583A1 (en) | Tetrahydrocurcuminoid-metal complexes, manufacturing methods thereof, and uses thereof | |
US20100166796A1 (en) | Method of increasing cellular function and health of glutathione deficient animals | |
JP6443804B2 (en) | Natural killer cell activity promoter | |
KR20220154210A (en) | Coenzyme Q production promoter and coenzyme Q production promotion method | |
JP5922862B2 (en) | Mitochondrial function improver | |
JP2009107987A (en) | Muscle enhancer | |
WO2003047528A2 (en) | Supplements containing annatto extracts and carotenoids and methods for using the same | |
US20220362188A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
KR100515923B1 (en) | The bio conjugated proteins is process of produce | |
KR102275715B1 (en) | Pharmaceutical composition for anti-oxidant and anti-cancer comprising Coprinus comatus extract as effective material and manufacturing method for the same | |
WO2015002239A1 (en) | Oral ultraviolet resistance enhancer | |
JP6940864B2 (en) | Testicular disorders preventive and / or improver | |
Alsaadi et al. | The Biophysiological Impact of Alcoholic Extract of Turamic with or without Folic Acid in Awassi Ewes, Comparative Study | |
TWI607750B (en) | New use of lycopene and preparation of lycopene based on the same | |
Frez et al. | Properties of free and microencapsulated quercetin: A literature review | |
JP2024057941A (en) | Composition for improving mitochondrial activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: PROBIOTICSMART, LLC, WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUBOURDIEU, DANIEL J;LALL, RAJIV;SIGNING DATES FROM 20211119 TO 20220718;REEL/FRAME:060705/0536 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |